

日本国特許庁
JAPAN PATENT OFFICE

12.12.03

別紙添付の書類に記載されている事項は下記の出願書類に記載されている事項と同一であることを証明する。

This is to certify that the annexed is a true copy of the following application as filed with this Office.

出願年月日 2002年12月12日
Date of Application:

出願番号 特願2002-360972
Application Number:
[ST. 10/C] : [JP2002-360972]

REC'D 22 APR 2004	
WIPO	PCT


出願人 独立行政法人理化学研究所
Applicant(s): 株式会社ダナフォーム

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

2004年 4月 8日

特許庁長官
Commissioner,
Japan Patent Office

今井康夫



【書類名】 特許願
【整理番号】 P021480
【特記事項】 特許法第36条の2第1項の規定による特許出願
【あて先】 特許庁長官 太田 信一郎 殿
【国際特許分類】 C12N 15/10
【発明者】
【住所又は居所】 茨城県つくば市稲荷前22-8
【氏名】 林崎 良英
【発明者】
【住所又は居所】 埼玉県和光市広沢2番1号 理化学研究所内
【氏名】 ピエロ カルニンチ
【発明者】
【住所又は居所】 東京都港区三田1丁目3番35号 株式会社ダナフォーム内
【氏名】 アレキサンダー レジャバ
【発明者】
【住所又は居所】 東京都港区三田1丁目3番35号 株式会社ダナフォーム内
【氏名】 マチイアス ハーベス
【発明者】
【住所又は居所】 東京都港区三田1丁目3番35号 株式会社ダナフォーム内
【氏名】 柴田 裕子
【特許出願人】
【識別番号】 000006792
【氏名又は名称】 理化学研究所
【特許出願人】
【識別番号】 501293666
【氏名又は名称】 株式会社ダナフォーム

【代理人】

【識別番号】 100099623

【弁理士】

【氏名又は名称】 奥山 尚一

【選任した代理人】

【識別番号】 100096769

【弁理士】

【氏名又は名称】 有原 幸一

【選任した代理人】

【識別番号】 100107319

【弁理士】

【氏名又は名称】 松島 鉄男

【手数料の表示】

【予納台帳番号】 086473

【納付金額】 35,000円

【提出物件の目録】

【物件名】 外国語明細書 1

【物件名】 外国語図面 1

【物件名】 外国語要約書 1

【ブルーフの要否】 要

【書類名】 外国語明細書

1. Title of Invention

**METHOD FOR IDENTIFYING, ANALYSING AND/OR CLONING
NUCLEIC ACID ISOFORMS**

2. Claims

Claims

1. A method for identifying, analysing and/or cloning nucleic acid isoforms comprising the steps of:
 - a) preparing at least two nucleic acid isoforms, complementary to each other;
 - b) hybridizing the at least two complementary nucleic acid isoforms and forming double strand RNA/RNA or DNA/DNA hybrids comprising unpaired regions;
 - c) recovering the RNA/RNA or DNA/DNA hybrids comprising unpaired regions from not hybridized nucleic acids and from nucleic acids not comprising unpaired regions ; and
 - d) identifying, analysing and/or cloning the recovered nucleic acid fragment comprising unpaired regions.
2. The method of claim 1, wherein the recovering of step c) is carried out by using at least one restriction enzyme which cuts free single strand nucleic acids but does not cut double strand nucleic acids and/or at least a restriction enzyme which cut double strand nucleic acids but does not cut unpaired regions.
3. The method of claim 2, wherein the restriction enzyme which cuts free single strand nucleic acids but does not cut double strand nucleic acids is Exo VII, Exonuclease I, Exonuclease T, Lambda Exonuclease, or T7 Exonuclease.
4. The method of claim 2, wherein at least one restriction enzyme which cuts double strand nucleic acids but does not cut unpaired regions is used.
5. The method of claim 4, wherein two restriction enzymes are used.
6. The method of claim 4 or 5, wherein the restriction enzymes cut at recognition sites comprising of 4 nucleotides of double strand nucleic acids but do not cut unpaired regions.
7. The method of claim 6, wherein the restriction enzymes are selected from HapII, HypCH4IV, AciI, HhaI, MspI, AluI, BstUI, DpnII, HaeIII, MboI, NlaIII, RsaI,

Sau3AI, Taq alpha I and Tsp 509I.

8. The method of any one of claims 1-7, wherein hybrids of RNA/RNA or DNA/DNA comprising unpaired regions are recovered from hybrid nucleic acids not comprising unpaired regions by using single strand nucleic acid-binding molecule.
9. The method of claim 8, wherein the single strand nucleic acid-binding molecule is bound to a tag.
10. The method of claim 8 or 9, wherein the nucleic acid to be recovered/single strand nucleic binding molecule/tag complex is recovered by use of a matrix which binds the tag.
11. The method of claim 8, wherein the single strand nucleic acid-binding molecule is a single strand nucleic acid-binding protein, antibody, antigen, oligonucleotide, a chemical group or chemical substance.
12. The method of claim 11, wherein the oligonucleotide which binds the tag is a random oligonucleotide.
13. The method of claim 12, wherein the random oligonucleotide is 15-30 nucleotides.
14. The method of claim 13, wherein the random oligonucleotide is 25 nucleotides.
15. The method of any one of claims 8-14, wherein the tag is biotin, digoxigenin, antibody, antigen, a protein or nucleic acid binding molecule and the matrix is avidin, streptavidin, digoxigenin-binding molecule, an antibody or its ligand and/or chemical matrix.
16. The method of any one of claims 8-15, wherein the tag is digoxigenin the matrix is a digoxigenin-binding molecule
17. The method of any one of claims 8-15, wherein the tag is biotin and the matrix is avidin or streptavidin.
18. The method of any one of claims 8-17, wherein the single strand nucleic acid-binding molecule is covalently attached to the matrix.
19. The method of any one of claims 8-18, wherein the matrix is associated to a solid matrix surface selected from the group consisting of metal beads, magnetic beads, inorganic polymer beads, organic polymer beads, glass beads and agarose beads.
20. The method of any one of claims 1-19, wherein hybrids of RNA/RNA or DNA/DNA comprising unpaired regions are recovered from hybrid nucleic acids and released from the single strand nucleic acid-binding molecule.

21. The method of any one of claims 1-20, wherein the recovered nucleic acids comprising unpaired regions are bound with Y-shaped oriented linkers comprising a sticky end.
22. The method of claim 21, wherein the Y-shaped oriented linker comprises a different marker sequence in each single strand arm.
23. The method of any one of claims 21-22, wherein the Y-shaped linker comprises a sticky end which hybridized with the sticky end of the fragment comprising the unpaired region.
24. The method of claim 23, wherein the sticky end of the Y-shaped linker hybridizes to the sticky end of the fragment comprising the unpaired region cut by the restriction enzymes of any one of claims 4-7.
25. The method of any one of claims 1-24, wherein the at least two nucleic acid isoforms are prepared from at least one nucleic acid library, biological sample, cell, tissue, organ or biopsy.
26. The method of claim 25, wherein the two nucleic acid isoforms are prepared from two or more different nucleic acid libraries, biological samples, cells, tissues, organs or biopsies.
27. The method of any one of claims 25-26 wherein the at least one of the at least two nucleic acid libraries, biological samples, cells, tissues, organs or biopsies is from tumoral source, from treated cells, and/or from cells undergoing apoptosis.
28. The method of any one of claims 1-27, wherein the nucleic acids comprising nucleic acids comprising unpaired regions as recovered at step 1), 2), 3) and/or 4) of claim 1, are stored as nucleic acid isoforms-enriched libraries, used for the analysis of isoforms, clones and/or used for the detection of further isoforms.
29. The method of claim 28, wherein the obtained libraries are alternative splicing-enriched libraries.
30. The method of any one of claims 1-29, wherein the recovered nucleic acids comprising unpaired regions are amplified and cloned.
31. The method of any one of claims 1-30, wherein the unpaired regions correspond to portions of genes that are differentially spliced.
32. The method of any one of claims 1-31, wherein the unpaired regions correspond to portions of related genes derived from different loci within the same genome.
33. The method of any one of claims 1-31, wherein the unpaired regions correspond to portions of unrelated genes derived from the same locus within a genome.
34. The method of any one of claims 1-31, wherein the unpaired regions correspond

to portions of related genes derived from different genomes.

35. The method of any one of claims 1-34, wherein the recovered and cloned nucleic acid comprise the whole sequence of an unpaired region.
36. The method of claim 35, wherein the unpaired region corresponds to an exon or intron.
37. The method of any one of claims 1-36, wherein the at least two complementary nucleic acid isoforms are prepared from starting materials by using at least two different RNA and/or DNA polymerases each of them recognizing a different promoter site.
38. The method of claim 37, wherein RNA transcripts are obtained from the starting materials by using RNA polymerases which recognize a different promoter site, and cDNAs are prepared from the RNA transcripts by using reverse transcriptase.
39. The method of claim 38, wherein the at least two RNA polymerases recognizing different promoter site are selected from the group consisting of T3 RNA polymerase, T7 RNA polymerase, SP6 RNA polymerase and K11 RNA polymerase.
40. The method of any one of claims 1-39, wherein a DNA polymerase and strand specific primers are used.
41. The method of any one of claims 1-39, wherein a DNA polymerase and strand specific primers are used for linear amplification.
42. The method of any one of claims 40-41, wherein the DNA polymerase is Taq DNA Polymerase, DNA Polymerase I Large (Klenow) Fragment, or Exonuclease Minus
43. The method of claim 1, wherein the in step c) the nucleic acid isoforms are recovered by using linkers or primers.
44. The method of claim 43, wherein the linker or primer recognizes specific sequence sites.
45. The method of claim 43, wherein the isoform nucleic acids are recovered by using a linker and DNA or RNA ligase.
46. The method of claim 45, wherein the ligase is T4 DNA ligase, E.coli DNA ligase, RNA ligase or T4 RNA ligase.
47. The method of any one of claims 1-46, wherein vectors or primers are used to introduce recognition sites for the 4bp cutters restriction enzymes of claims 4-7 at the ends of the nucleic acid isoforms.
48. The method of any one of claims 1-47, wherein the nucleic acid isoforms are

prepared from fragmented genomic DNA, cDNA, full-length cDNA, mRNA and/or RNA.

49. The method of any one of claims 1-48, wherein the isoforms are full-length cDNAs or a fragment thereof comprising the unpaired region.
50. The method of claim 49, wherein the isoform substantially comprises the unpaired region.
51. A cloning vector comprising the isoform obtained according to claims 1-50.
52. A host cell comprising the vector of claim 51.
53. A method for the preparation of isoform polypeptides comprising preparing the culture host cell of claim 52
54. A method for preparing an isoform polypeptide comprising the step of preparing a isoform nucleic acid according to any one of claims 1-50 and preparing the corresponding isoform polypeptide by using free-cell in-vitro or in vivo system.
55. A method for the identification of isoform polypeptides using the information obtained according the method of any one of claims 1-54.
56. A method for the detection and/or isolation of nucleic acid isoforms comprising the steps of:
 - i) preparing at least one oligonucleotide probe comprising the whole or part of sequence of an unpaired region identified and/or cloned according to any one of claims 1-50;
 - ii) hybridizing the oligonucleotide probe to nucleic acids comprising nucleic acid isoforms; and
 - iii) isolating the nucleic acid isoforms.
57. The method of claim 56, wherein the oligonucleotide probe is used to isolate full-length nucleic acid isoform.
58. The method of any one of claims 56-57, wherein the oligonucleotide probe comprise at least part of or the entire sequence of one exon or intron.
59. A method for the determination of sequence variation of isoforms of claims 1-58, comprising the full-length or partial sequencing of the isoform.
60. The method of any one of claims 1-59, wherein the sequence information of the sequence isoforms is used for the design of sequencing primers.
61. The method of any one of claims 1-59, wherein the obtained isoform sequencing data are aligned to the genome, to genomic sequencing data and/or to cDNA sequencing data to obtain genetic information.
62. The method of claim 61, wherein the information is on alternative splicing.

63. The use of information obtained from any one of claims 1-62, for the preparation of a nucleic acid probe.
64. The nucleic acid probe of claim 50.
65. Use of the information obtained from the method of any one of claims 1-63, for the detection and/or diagnosis of a disease, disease condition, pathology, a physiological condition, for assessing toxicity, for assessing the therapeutic potential of a test compound and/or for assessing the responsiveness of a patient to a test or treatment.
66. Method for recovering of full-length cDNAs from cDNA libraries, biological samples, cells, tissues, organs or biopsies is from tumoral source, from treated cells, and/or from cells undergoing apoptosis by using the information on alternative splicing of claim 62.
67. Method for recovering of full-length cDNAs according to any one of claims 1-66 from cDNA libraries, biological samples, cells, tissues, organs or biopsies is from tumoral source, from treated cells, and/or from cells undergoing apoptosis by using the information on alternative splicing.
68. Use of isoforms obtained according to the method of any one of claims 1-52 and/or the nucleic acid probe of claim 64 for the preparation of non-soluble supports for hybridization in situ.
69. A non soluble support comprising at least an nucleic acid comprising an unpaired region prepared according to the method of any one of claims 1-62, a nucleic acid complementary to the unpaired region and/or the probe of claim 64, fixed, applied and/or printed thereon.
70. The support of any one of claims 68-69, which is a solid matrix.
71. The support of any one of claims 68-69, which is a microarray.
72. Use of the support of any one of claims 68-71, for the identification and isolation of nucleic acid isoform.
73. Use of the support of any one of claims 68-71, for in situ hybridization.
74. Use of the support of any one of claims 68-71, for the detection and/or diagnosis of a disease, disease condition, pathology, a physiological condition, for assessing toxicity, for assessing the therapeutic potential of a test compound, for assessing the responsiveness of a patient to a test or treatment, for the detection of nucleic acids and/or for the detection of nucleic acid isoforms.
75. Use of genetic information obtained according to any one of claims 1-74 for detecting and/or isolating nucleic acids from a support, microarray, nucleic acid

library, biological sample, cell, tissue, organ and/or biopsy.

76. A computer program and/or software applied on a medium for the analysis of genetic information obtained according to any one of claims 1-75.
77. A computer program and/or software applied on a medium for the alignment of the nucleic acid isoforms sequences or information obtained according to any one of claims 1-76 to genomic and/or cDNA sequence information.
78. A computer program and/or software applied on a medium for the prediction, determination and/or analysis of functional domains of polypeptides that derive from nucleic acid isoforms sequence or information obtained according to any one of claims 1-77.

3. Detailed Explanation of the Invention

Field of the invention

The present invention relates to the identification, analysis, selection, preparation and/or cloning of nucleic acid isoforms.

Background art

The 25-years-old discovery that eukaryotic genes consist of introns and exons was a fundamental breakthrough in our understanding of gene structures and gave rise to a new field in life science focusing on mRNA processing. As introns and exons are both transcribed into a pre-mRNA, an additional step is required to convert the initial pre-mRNA into a mature mRNA, in which the non-coding introns have been removed and the coding exons have been linked together in the correct order. The so-called splicing process, by which introns are excised from pre-mRNAs and exons are re-associated in a specific manner, is essential for the correct processing of mRNA molecules and for a correct translation of the genetic information into proteins.

The pre-mRNA splicing reaction is carried out by splicesomes, which are ribonucleoprotein complexes containing five small nuclear RNAs (snRNAs) and a large number of associated proteins. Splicesomes recognize specific 5' and 3' splice sites located at exon-intron boundaries (splice donors and splice acceptors). The following splicing reaction requires that first the 5' end of the intron is joined to an adenine residue in the branch point sequence upstream of the 3' splice site to form a branched intermediate, the so-called an intron lariat; in a second step then two exons

are ligated and the intron lariat is released from the complex. In this process the exon recognition is a fundamental problem of the pre-mRNA splicing. The splicing machinery must be able to recognize small exon sequences (~150bp) located within vast stretches of intronic RNA (on average about 3.5kb). Moreover, 5' and 3' splice sites are in general poorly conserved, and introns often contain large numbers of cryptic splice sites similar to a 5' or 3' splice-site consensus sequences. Therefore cryptic splice sites can be selected for splicing when normal splice sites are altered by mutagenesis. Beside the splicing donor and acceptor sites, specific sequence elements in exons were characterized as exonic splicing enhancers (ESEs), which interact with a family of conserved serine/arginine-rich splicing factors, the so-called SR proteins. As those ESEs are needed to recruit the splicing machinery and guide it to the flanking 5' and 3' splice sites, exon sequences are under multiple evolutionary constraints to conserve not only for the coding information but also for the ability to bind to SR proteins. Such an evolutionary selection may have contributed to the development of mechanisms for stage and tissue specific splicing phenomena.

Once exon recognition is completed, the flanking splice sites of two exons must be joined in the correct 5'-3' order to prevent exon skipping. Splicing factors, which are bound to the carboxy-terminal domain (CTD) of RNA polymerase II, interact with exons as they emerge from the exit pore of the polymerase. These interactions tether the newly synthesized exon to the CTD until the next exon is synthesized. Although coupling transcription to splicing should prevent exon skipping in constitutively spliced pre-mRNAs, exon skipping can be desired during stage and tissue specific alternative pre-mRNA splicing. In such cases, the presence or absence of regulatory proteins can determine whether or not an exon is recognized and subsequently included in the mature mRNA.

Beside its principle importance for gene regulation and expression, mRNA splicing recently became a focus of genomic research after the sequencing of eukaryotic genomes. The analysis from whole genome sequences from as different organisms as humans, the nematode *C. elegans*, the fly *Drosophila melanogaster*, and the complex bacteria *Streptomyces* reviled unexpectedly small differences in the total number of genes encoded by each genome. Thus the human genome would encode only about 1.5 times as many genes as that of the relatively simple nematode *C. elegans*. This uncanonical phenomenon may be explained by mechanisms of alternative splicing, which were increasingly applied during the development eukaryotes. Due to differential splicing of its pre-mRNA a single gene can encode

for multiple isoforms on the protein level of which each isoform is distinct by alternative exon usage.

An understanding of such alternative splicing mechanisms and the distinct proteins resulting thereof becomes ever more important as an increasing number of reports point to human diseases and aging aberrations related to miss-splicing or a lack of alternatively spliced isoforms. Therefore, there is a huge demand for the detection and characterization alternatively spliced mRNA molecules to allow for the development of novel means in assay development and to identify targets for drug discovery as well as diagnostics.

The identification of sequence variations is thus far a complex and tedious task. In particular for the identification of different splice variants, it is necessary to clone related sequences out of the same or many distinct cDNA libraries and forward individual clones derived thereof to further analysis. Although an initial analysis of individual clones can be performed by restriction digest followed by electrophoretical separation of the resulting fragments, the entire genetic information of the different clones can only be obtained from full-length sequencing and further computational alignments. This process is quite time consuming and cost effective and furthermore does not allow for an up scaling for high throughput analysis. The lack of effective means for the parallel analysis of sequence variations and their application to studies on differentially spliced pre-mRNA molecules is a clear limitation in out of today's genomic research and development projects.

US patent 6,251,590 discloses a method for identification and/or cloning of differentially spliced nucleic acids from a standard biological sample and a test biological sample. The method consists in preparing a plurality of RNAs from one sample and a plurality of DNAs from the other sample followed by hybridization and formation of hybrids RNA/DNA. The RNA molecule comprising an unpaired region corresponding to the portion of the gene, which is differentially spliced between the samples, is then identified. The method disclosed in US 6,251,590 is limited to the preparation of hybrids RNA/DNA since the strategy for identification of unpaired region is carried out essentially by means of use of enzyme RNase H. This enzyme cuts RNA bound to DNA, but does not cut single strand RNA (the unpaired region), which can then be recovered. This method however shows several drawback and lack of efficiency. The problem is that 1) the RNase H cuts RNA hybridized to DNA in fragments of 3-10 nucleotides, and 2) RNA which is only partially hybridized DNA is released in the mixture RNA fragments of

generally 10-50 nucleotides after cut of RNase H. It results difficulties to distinguish the unpaired region, as it can be a short fragment for example of about 20 bases, from the RNA fragments of 1-10 and 10-50 nucleotides. The researcher needs to carry out a size selection method, for example by electrophoresis, but the presence of impurities cannot be avoided. He therefore, needs to sequence all the recovered fragments in order to determine the fragment corresponding to the unpaired region. This method is therefore not efficient as it results in a high background of false positives and gives rise to artifacts.

The authors of US 6,251,590 propose a further method for recovering of RNA molecule comprising the unpaired region. It consists of carrying out a reverse transcription reaction by using random primers. The problem is, however, that the random primer can hybridize the RNA molecule comprising the unpaired region at any position, including a position inside the unpaired region. The consequence of this strategy is that there is no certainty that the full-length of the unpaired region is recovered. On the contrary, small portions of sequence or fragments of the unpaired region are highly likely to be recovered. Only this strategy therefore results lack of efficiency and accuracy.

There is therefore the need in this field of research of improved and efficient methods, which may assure the identification, selection and preparation of nucleic acids which result from the same or from related genes.

The method of the present invention overcomes the problems of the art and provides an efficient method for the identification, analysis and/or cloning of such nucleic acids.

Summary of the invention

The present invention provides a new, improved and flexible method for the identification, analysis, cloning and/or preparation of nucleic acid variants or isoforms.

The present invention provides a method for identifying, analyzing and/or cloning nucleic acid isoforms comprising the steps of:

- a) preparing at least two nucleic acid isoforms, complementary to each other;
- b) hybridizing the at least two complementary nucleic acid isoforms and forming double strand RNA/RNA or DNA/DNA hybrids comprising unpaired regions (also indicated as loop);

- c) recovering the RNA/RNA or DNA/DNA hybrids comprising unpaired regions from not hybridized nucleic acids and from nucleic acids not comprising unpaired regions ;
- d) identifying, analyzing and/or cloning the recovered nucleic acid fragment comprising unpaired regions.

According to a particular aspect of the invention, the recovery step c) as above is carried out by using at least one restriction enzyme which cuts free single strand nucleic acids but does not cut double strand nucleic acids and/or at least one or more restriction enzymes, which cut double strand nucleic acids but does not cut unpaired regions.

The restriction enzymes, which cut double strand nucleic acids but do not cut unpaired regions, can be any kind of restriction enzyme for this purpose. Restriction enzymes, which cut at recognition sites comprising of 4 nucleotides of double strand nucleic acids but do not cut unpaired regions can be used preferable.

According to an embodiment of the inventions, hybrids of DNA/DNA or RNA/RNA comprising unpaired regions are recovered from hybrids nucleic acids not comprising unpaired regions by using nucleic acid single strand-binding molecule, for example single strand nucleic acid-binding protein, antibody, antigen, oligonucleotide, a random oligonucleotide, a chemical group or chemical substance. The nucleic acid single strand-binding molecule is preferably bound to a tag, for example, biotin, digoxigenin, antibody, antigen, a protein or nucleic acid binding molecule. The tag can be recovered by binding a matrix, for example avidin, streptavidin, digoxigenin-binding molecule, an antibody or its ligand and/or chemical matrix associated with solid matrix surface like metal beads, magnetic beads, inorganic polymer beads, organic polymer beads, glass beads and agarose beads.

According to a further embodiment, the hybrids of DNA/DNA or RNA/RNA can be recovered by using by using linkers or primers. For example, linkers or primers which recognize specific sequence sites introduced during the preparation of isoforms of step a) as above.

According to a further embodiment, the invention provides a linker system for introducing orientation of sequences. According to one realization, shaped linkers, preferably asymmetric linkers are used to bind the hybrids as above. Preferably, the Y-shaped linkers comprises sticky end, which hybridize to the hybrids or hybrids

fragments comprising the unpaired regions. The nucleic acids isoforms oriented with this system can be easily distinguished during sequencing and bioinformatic analysis.

All the hybrids or hybrid fragments comprising the unpaired regions obtained or isolated as above can be stored as such as source of isoforms enriched-libraries or can be analyzed by various means including but not limited to be sequenced and analysis for the determination for genetic information.

Further, the present invention provides a method for using genetic information obtained from the method according to the invention for preparing nucleic acids useful for the subsequent identification, selection, analysis, isolation and/or preparation of further nucleic acid isoforms.

According to one embodiment, the nucleic acids useful for identification and isolation of further isoforms can be applied, fixed and/or printed on a support, like a microarray and used for isoform screening.

According to a further embodiment, the invention provides for computer program or software, preferably applied on a medium, for the prediction, determination and/or analysis of generic information and proteins derived thereof obtained according to the embodiments of the invention.

Brief description of the drawings

Figure 1 - Principle of mRNA splicing process.

Figure 2 – A general outline of the steps involved in the method of the invention.

Figure 3 – Preparation of strand specific hybridization probes.

Figure 4 – Preparation of PCR products.

Figure 5 – Sample-specific ssDNA synthesis.

Figure 6 – Hybridization of sample-specific ssDNA molecules.

Figure 7 – Incubation of hybridization products with Exonuclease VII.

Figure 8 – Incubation of hybridization products with 4 bp cutters restriction enzymes.

Figure 9 – Capture of loop structures (unpaired region) with biotinylated and randomized oligonucleotide.

Figure 10 – Structure of Y-shape like asymmetric linkers.

Figure 11 – Linker ligation applying Y-shape like asymmetric linkers

Figure 12 – Cloning into vector for sample analysis.

Detailed description of the invention

The present invention provides a new, improved and flexible method for the identification, analysis, cloning and/or preparation of nucleic acid variants or isoforms.

For the purpose of the present invention, "nucleic acid isoform" or "nucleic acid variant" means nucleic acids, which differ in sequence and are generated from the same gene or from related genes. In the present description either terms "isoform" or "variant" may be used.

A nucleic acid isoform may be for example but not limited to: 1) the consequence of a mutation, like a deletion and insertion, within a gene; 2) due to alternative splicing of exons and introns within a single primary RNA transcript; 3) be the product of trans-splicing, that is, the splicing of RNA exons generated from both strands of DNA into a single transcript; 4) the product of the same gene at difference stage of development, a different organ or tissue and case of disease and transformation; 5) may refer to nucleic acids generated from related genes; 6) a 'paralog', that is, a nucleic acid generated from a gene related to another similar gene by duplication within a genome; 7) a 'ortholog', that is, a nucleic acid generated from a gene with similar function to another gene in an evolutionarily related species; 8) a naturally occurring nucleic acid related or similar to an artificial nucleic acid; or 9) an 'artificial nucleic acid' related or similar to a naturally occurring nucleic acid".

The isoforms or variants prepared according to any embodiment of the present invention comprise unpaired regions (or loop) wherein these regions are known, unknown or partially unknown regions.

As above said, the unpaired region may be the consequence of different phenomena, including but not limited to alternative splicing process. Figure 1 shows a schematic example of principle of alternative splicing process.

Figure 2 and 3, show outlines of the some steps and embodiments of the method according to the invention.

The present invention provides a method for identifying, analyzing and/or cloning nucleic acid isoforms comprising the steps of:

- a) preparing at least two nucleic acid isoforms, complementary to each other;
- b) hybridizing the at least two complementary nucleic acid isoforms and forming double strand RNA/RNA or DNA/DNA hybrids comprising unpaired

regions (also indicated as loop);

- c) recovering the RNA/RNA or DNA/DNA hybrids comprising unpaired regions from not hybridized nucleic acids and from nucleic acids not comprising unpaired regions ;
- d) identifying, analyzing and/or cloning the recovered nucleic acid fragment comprising unpaired regions.

The at least two nucleic acid isoforms have to be complementary to each other, that is, one sense and the other antisense, in order to hybridize and form hybrids of DNA/DNA and RNA/RNA comprising an unpaired region (as shown in Figure 6).

The at least two nucleic acid isoforms may be obtained from at least one nucleic acid library, biological sample, cell, tissue, organ or biopsy. The isoforms can also be prepared from two or more different nucleic acid libraries, biological samples, cells, tissues, organs or biopsies. The isoforms can be obtained for example from a standard sample and from one or more test sample, as indicated in US 6,251,590 B1, herein incorporated by reference. The test or standard sample can be for example a nucleic acid library, biological sample, cell, tissue, organ or biopsy. The test sample can be preferably a tumoral source, treated cell, and/or from cell undergoing apoptosis or other sources under physiological or pathological conditions as indicated in US 6,252,590.

Samples from different biological stages can also be selected for analysis. These stages can include but are not limited to different time points or developmental stages of the same tissue or cell, or are derived from different tissue samples from the same organism. In another embodiment the invention can be applied to analyze and compare the genetic information of distinct organisms. In its standard application, the invention is used to compare the content of two different samples reflecting on two biologically distinct conditions. However, the invention is not limited to the simultaneous analysis of two samples as mixtures of distinct samples can be applied as well, where depending on the nature of the samples used and their biological context individual samples within a mixture of samples can be distinguished for their origin by specific flanking sequence sites (also indicated as flanking sequence tags or flanking sequence marker sites). In another embodiment of the invention those flanking sequence tags are used to discriminate between samples of distinct origin within a mixture of nucleic acid molecules by differential selection for amplification by specific PCR primers.

As samples individual nucleic acid complementary isoforms prepared from the standard and test samples, nucleic acids or any mixture of individual nucleic acid molecules derived from RNA preparations, from fragments of genomic DNA, or cDNAs can be applied. The invention can use but is not limited to the use of DNA molecules cloned or recombinant into cloning vectors or phages for their better handling and amplification. However, also linear DNA molecules can be directly applied for the invention or made available for the invention by an amplification step. The samples to be compared by the means of the invention can be obtained from any kind of plurality of nucleic acids including but not limited to the use of mRNA, cDNA and genomic DNA samples, and the samples can be mixed and combined in any order depending on experimental needs.

The invention can make use of many kinds of different starting materials and thus the invention is not limited to the use of DNA libraries only. A DNA library can contain any kind of DNA fragment or DNA fragments derived from natural sources or of an artificial nature directly synthesized or obtained by manipulation of genetic material obtained from an organisms, a tissue, a cell line or alike. Furthermore the DNA material cloned into a DNA library can comprise information derived from RNA and transcribed into cDNA or can be derived from fragmented genomic DNA. However, the invention is not limited to the use of nucleic acids derived from a DNA library as any individual DNA fragment derived from natural sources or of an artificial nature directly synthesized or obtained by manipulation of genetic material obtained from an organisms, a tissue, a cell line or alike can be applied to perform the invention and to compare the sequence information of such a DNA fragment to that of one or more DNA fragments. In one embodiment the invention is applied to the analysis of two cDNA libraries, which are compared for their content of nucleic acid isoforms. Then, the isoform complementary molecules can also be prepared from one or more libraries or sample wherein the nucleic acids are subjected to denaturation and re-association.

As standard and/or test sample one or more cDNA libraries can also be used (for instance the cDNA libraries described by Okazaki et al., the Fantom Consortium and RIKEN exploration research group, Nature, December 2002, Vol.420, 563-573). cDNA molecule can be prepared according to any method known in the art (see Sambrook and Russel, Molecular Cloning, 2001, Cold Spring Harbor Laboratory Press), for example Maruyama K., and Sugano S., 1994, Gene, 138: 171-174 or full-length cDNAs prepared according to the Cap-trapper methodology, which may

be normalized and/or subtracted (Carninci et al., October 2000, *Genome Research*, 10:1617-1630). cDNA library can be prepared inserting cDNAs or full-length cDNA into vectors, for example as described in Carninci et al., September 2001, *Genomics*, Vol.77, (1-2):79-90. As indicated above, also genomic DNA, ESTs, RNA and/or mRNA can also be used as starting point for the preparation of complementary nucleic acid isoforms. However, the invention is not limited to the use of two or more pluralities of nucleic acids as one sample can be comprised of a single nucleic acid molecule such as a clone holding a cDNA or a genomic fragment, whose genomic information can be studied by the means of the invention for its presence in a modified or altered or thus alternatively splice variant or variants in any given context of a biological or artificial sample provided in the form of a yet to be different plurality of nucleic acids.

Complementary nucleic acid isoforms (step a) can be prepared to any method known in the art (for example, see Sambrook and Russel, 2001, as above). According to one embodiment, the complementary cDNA strands are prepared by transcribing sense and antisense isoforms from one or more samples by using at least two complementary nucleic acid isoforms as starting materials by using at least two different RNA and/or DNA polymerases each of them recognizing different promoter sites. According to one realization, RNA transcripts are obtained from the starting materials by using RNA polymerases, which recognize a different promoter site, and cDNAs are prepared from the RNA transcripts by using reverse transcriptase (see Figures 4-5). The at least two RNA polymerases recognizing different promoter site are selected from T3 RNA polymerase, T7 RNA polymerase, SP6 RNA polymerase and K11 RNA polymerase or mutant thereof (see US 6,365,350).

Any DNA polymerase for this use known in the art can be used (Sambrook and Russel, 2001, as above). A DNA polymerase and strand specific primers can also be used for this purpose including but not limited to the Taq DNA Polymerase or the DNA Polymerase I Large (Klenow) Fragment, which is Exonuclease minus.

According to one embodiment, as described in figures 2-5, two sets of single stranded DNA molecules are prepared, one set from sample 1 (or condition 1 as indicated in the figures), for example melanocyte full-length cDNA library, and the other set from sample 2 (or condition 2), for example melanoma full-length cDNA

library. The two sets of libraries may be amplified, according to standard amplification methodology (see Sambrook and Russel, 2001), for example as phages, as plasmid DNA or as DNA fragments by PCR. The two sets of double strand cDNAs are reverse transcribed using T3 RNA polymerase which recognizes the T3 promoter site in the first set of library and T7 RNA polymerase which recognizes the T7 promoter site in the second set of library, respectively (see figures 4-5). As a consequence, two sets of RNA transcripts, complementary to each other (except for the regions of distinct or missing sequences which are here indicated as unpaired regions or loop) are transcribed. RNA as described and obtained by the means of the invention can be applied to and used directly for performing the invention on the level of RNA/RNA hybrids, whereas in part unpaired and thus loop structure forming hybrids can be enriched by the means of the invention as disclosed below for the isolation of loop structures formed by DNA/DNA hybrids.

Using primers and DNA polymerases, DNA strands are synthesized according to standard technologies (Sambrook and Russel, 2001, as above).

The RNA strands are then removed from the double DNA/RNA strands, by using standard technologies (Sambrook and Russel, 2001, as above), for example causing hydrolysis of RNAs by addition of NaOH.

The products obtained are two sets of single strand DNAs complementary to each other (indicated as lower and upper strands in figure 5).

As said above, these two complementary sets of nucleic acids correspond two isoforms, which are complementary to each other except for the regions of distinct or missing sequences, which are indicated as unpaired regions or loop. These unpaired regions correspond, for example, to portions of related genes derived from different loci within the same genome, portions of unrelated genes derived from the same locus within a genome, portions of related genes derived from different genomes. They may correspond to deletions, insertions, exons and/or introns.

The two sets of complementary cDNAs are hybridized in order to form hybrids of DNA/DNA, which comprises one or more unpaired regions, forming structures as shown in schematic form in figure 6 (this step corresponds to step b).

The method as above has been described for the preparation of hybrids of DNA/DNA, however hybrids of RNA/RNA are also within the scope of the present invention. Hybrid of RNA/RNA can be prepared according to standard technologies. Preparation or mixture of hybrids DNA/DNA or RNA/RNA as above described can be stored as source of nucleic acid isoforms-enriched libraries or can be used for the

isolation of the full-length unpaired region.

The preparation of hybrids of DNA/DNA as above can be treated in order to recovering the hybrids of DNA/DNA comprising the unpaired regions from not hybridized or partially hybridized nucleic acids or nucleic acid regions and from nucleic acids hybrids not comprising unpaired regions.

Both treatments can be carried out independently from each other or simultaneously and in any order.

According to one embodiment, the removal of not hybridized or partially hybridized nucleic acids or nucleic acid regions is carried out by using at least one restriction enzyme which cuts free single strand nucleic acids but does not cut double strand nucleic acids. Restriction enzymes which cut free single strand nucleic acids but does not cut double strand nucleic acids are exonucleases for example: Exo VII, Exonuclease I, Exonuclease T, Lambda Exonuclease, T7 Exonuclease. These kinds of enzymes however are not limited to this list. Further enzymes known to those skilled in this field of the art may also be used. In particular, Exo VII works both in 5'>3' and 3'>5' direction, however any other exonucleases working in 3'>5' direction may be used on their own or in any given combination to reduce the background or artifacts caused by DNA/DNA hybrids with single stranded DNA overhangs.

The effect of use of restriction enzymes, which cut free single strand nucleic acids but does not cut double strand nucleic acids, is shown in schematic way in figure 7. Single strand nucleic acids, which have not hybridized, and those regions not hybridized are digested by the enzymes as above, leaving only double strand DNA/DNAs.

Following the treatment with Exonucleases as above or independently from that treatment, a step of recovery of DNA/DNA hybrids comprised unpaired regions from hybrids or nucleic acids not comprising unpaired region may be carried out. To this purpose, at least a restriction enzyme, which cut double strand nucleic acids but does not cut unpaired regions, may be used. Preferably, two restriction enzymes, which cut double strand nucleic acids but do not cut unpaired regions are used.

Restriction enzymes, which cut at recognition sites comprising of 4 nucleotides of double strand nucleic acids but do not cut unpaired regions are preferably used. A non-exclusive list of restriction enzymes which cut double strand nucleic acids but does not cut unpaired regions are selected from HapII, HypCH4IV, Acil, HhaI, Mspl, AluI, BstUI, DpnII, HaeIII, MboI, NlaIII, RsaI, Sau3AI, Taq alpha I and Tsp

5091.

Other suitable restriction enzymes, which are apparent to those skilled in this field of the art may also be used.

By using these kinds of restriction enzymes double strands DNA not comprising unpaired regions are cut. Only small fragments of hybrid isoforms comprising the unpaired regions are not cut by these enzymes.

The method of treatment for removal of unpaired regions from not hybridized nucleic acids and from nucleic acids not comprising unpaired regions by using at least one restriction enzyme which cuts free single strand nucleic acids but does not cut double strand nucleic acids (as above disclosed) and/or at least a restriction enzyme which cut double strand nucleic acids but does not cut unpaired regions (as above disclosed) are useful for the method according to the invention (as outlined in figures 2 and 3) however are not limited to that use. Accordingly, a general method for the recovery and isolation of nucleic acids comprising one or more unpaired regions by using either or both the above methods of use of restriction enzymes is also within the scope of the present invention.

Preparation of hybrid isoforms comprising the unpaired regions can be recovered and isolated according to methodologies known in the art. For example by using single strand nucleic acid-binding molecule. Single strand nucleic acid-binding molecule may be a single strand nucleic acid-binding protein, antibody, antigen, oligonucleotide, a chemical group or chemical substance. The oligonucleotide can be an oligonucleotide having random sequence, preferably a random oligonucleotide of 15-30 nucleotides, preferably of 25 nucleotides (it may be indicated as "25N"). A single strand nucleic acid-binding protein can be any protein having this characteristic (see Sambrook and Russel, 2001, as above). Proteins capable of binding single strand nucleic acids can be for example the E.coli single-stranded DNA binding proteins (SSB) produced by Promega, Catalog number M3011, which bind with high affinity to single-stranded DNA but do not bind to double-stranded DNA (see also Sancar et al., 1981, Proc. Natl. Acad. Sci., USA 78, 4274; Krauss et al., 1981, Biochemistry, 20, 5346). Single strand nucleic-binding proteins are also disclosed for example in EP 1041160 A1 (incorporated by reference). Other single strand nucleic acid-binding substances are disclosed for example in EP 0622457 A1 (incorporated by reference).

Single strand nucleic acid-binding substances are preferably bound to a tag molecule. A tag molecule may be selected from biotin, digoxigenin, antibody, antigen, a

protein and nucleic acid binding molecule. The single strand nucleic acid-binding molecule/tag molecule complex may be recovered by using a matrix. A matrix may be selected from avidin, streptavidin, digoxigenin-binding molecule, an antibody and its ligand and/or chemical matrix. The above lists of tags and matrices are, however, not limited to the compounds above indicated.

When the tag is biotin, the matrix may be avidin or streptavidin. When the tag is digoxigenin, the matrix may be digoxigenin-binding molecule (see Roche Catalog). When the tag is an antigen, the matrix may be the antibody. The single strand nucleic acid-binding molecule can also be covalently attached to the matrix. For example is case of oligonucleotide with an amino group, which can be used for covalent binding.

The recovery of the desired nucleic acid isoforms is preferably carried out when the matrix is conveniently associated to a solid matrix surface. The matrix solid surface may be selected from metal beads, magnetic beads, inorganic polymer beads, organic polymer beads, glass beads and agarose beads. Inorganic polymers include silica, ceramics, and the like. Organic polymers include polystyrene, polypropylene, polyvinyl alcohol, and the like. Metals include iron, copper, and the like.

Examples of tags, matrices and matrix solid surfaces can be found in EP 0622457 A1 (incorporated by reference).

A schematic example of the recovery as described above is shown in figure 9.

Hybrids of DNA/DNA or RNA/RNA isoforms comprising unpaired regions are isolated in this way from hybrids not comprising unpaired regions and are recovered by being released from the single strand nucleic acid-binding molecule according to standard methodologies, for instance by heating, for example 40-60, preferably 50 degrees C. In case of use of random oligonucleotide as single strand nucleic acid-binding molecule, a light heat is enough for releasing the hybrid isoforms from the single strand nucleic acid-binding molecule because the random oligonucleotide is not perfectly hybridized.

Preparations of isoforms as obtained from the above method can be stored as isoforms-enriched libraries or can be processed for the next step for the preparation of isoform with unpaired regions.

One situation which may happen in preparing hybrids of DNA/DNA and RNA/RNA is that the two DNAs (or the two RNAs) of the hybrid lack orientation, and during sequencing and/or further bioinformatic analysis is not clear if the two DNAs (or two RNAs) are complementary or sense molecules.

In order to overcome this problem, present inventors also provide a method for introducing orientation into each strand of the hybrid isoforms and this method represent a further embodiment of the present invention.

This embodiment consists in the preparation of Y-shaped linkers (see figures 10 and 11). These kinds of linkers consist of a double stranded body region and two single strand arms. Y-shaped linkers have been disclosed for example by Tazavoie and Church, 1998, Nat. Biotechnology, 16: 566-571.

According to the embodiment of the invention, each arm of the Y-shaped linker comprises a different specific marker site sequence or tag sequence. For instance, one arm may have the marker sequence (1) and the other arm the marker (2). When sequenced and analysed the sequences having the marker (1) and the nucleic acid sequences having the marker (2) will be treated as complementary nucleic acid sequences. One or more kind of Y-shaped linkers can be used at the same time if required to provide distinct overhangs for ligation. However, beside the overhang for the ligation, only one kind of linker can be used (see also figures 10, 11).

The Y-shaped linker can be attached to the hybrid DNA/DNA or RNA/RNA isoforms recovered according to any method known in the art (Sambrook and Russel, 2001, as above). For example by using RNA or DNA ligase. Examples of these ligases are T4 DNA ligase, E.coli DNA ligase, RNA ligase, T4 RNA ligase.

According to a preferred embodiment, the Y-shaped linkers have a sticky end, at the end of the double stranded body, which hybridizes to the sticky ends of the hybrid double strand nucleic acids to be recovered (in the present case hybrid DNA/DNA or RNA/RNA isoforms comprising the unpaired region). Specific sticky ends of the hybrid nucleic acids can be introduced by specific restriction enzymes. For example, when 4 cutter restriction enzymes, as above indicated, are used to digest double stranded nucleic acids, the Y-shaped linkers can be prepared having sticky end capable to hybridize to the hybrid DNA/DNA isoforms sticky ends.

According to another embodiment, the sticky end of the linker are of random sequence so that they can hybridize to any kind of sticky end of the hybrid nucleic acids.

The use of the Y-shaped linker to impart orientation is not limited to bind the hybrid double stranded isoforms of the invention but can applied in general to recover and to impart orientation to any double stranded nucleic acids. Accordingly, the present invention also discloses a method for imparting orientation to the two strands of double stranded nucleic acids by using Y-shaped linkers as above described.

The hybrid DNA/DNA or RNA/RNA isoforms comprising the unpaired region bound to the linkers disclosed as above can be amplified, for instance by one or more cycles of PCR (see figure 11) and cloned (see figures 11, 12). The cloning can be carried out according to any technique known in the art (see for example Sambrook and Russel, 2001, as above). For example using cloning vectors (see figure 12). Methods for preparing cloning vector and cloning is disclosed for example in WO 02/070720 A1 (incorporated by reference).

With reference to systems for recovering and/or cloning hybrid DNA/DNA or RNA/RNA isoforms comprising the unpaired regions, other methods are available. For example hybrids of RNA/RNA can be recovered and/or cloned by reverse transcription upon the RNA/RNA hybrids, according to standard methods, by using primers which recognized specific sequence sites (also indicated as recognition sites or sequence tags) of the RNAs which may have been introduced in the library phage or vector, during amplification step (figures 3, 4), or during the synthesis of RNA (figure 5). For instance, with reference to figure 4, the specific recognition sites can be introduced with the primers comprising the T3 and T7 promoter sites.

The isoform as recovered as above in a cloned vector (figure 12) can be introduced into a host cell according to standard methods (Sambrook and Russel, 2001, as above). The present invention therefore also provides for a method for the preparation of polypeptides comprising culturing the host cells as above.

Polypeptide of recovered isoform nucleic acids of the invention can also be prepared according to other known techniques like using cell-free in vitro (Kigawa et al., 1999, FEBS Lett., 442, 15-19. or in vivo systems.

The isoforms comprising the unpaired regions included in cloning vector can be sequenced and analysed.

The invention provides means for the preparation of DNA libraries specifically enriched for sequence isoforms, which define the difference between of two or more pluralities of the nucleic acid molecules. The libraries obtained according to the invention can be analysed by and applied to standard techniques known to a person skilled in the state of the art of molecular biology (see for example Sambrook and Russel, 2001, as above). The sequencing can be also carried out according to the description in Shibata et al., November 2000, Genome Research, Vol.10, (11): 1757-1771. This applications include but are not limited to partial or full-length sequencing of the insert, the preparation of probes for hybridization experiments,

and the sub-cloning or recombination of the inserts or parts thereof into other DNA molecules to allow for their manipulation or expression in the form of RNA or proteins. The recovered isoform comprised into the cloning vector can be in fact transferred into a vector suitable for sequencing, for instance according to the method described in Carninci et al., September 2001, Vol.77, (1-2), 79-90.

In another embodiment, the invention provides means for the analysis of sequence information derived from DNA or RNA molecules obtained during the realization of the invention. As those selected DNA or RNA molecules are enriched for DNA or RNA isoform fragments, which are distinct between the two or more analyzed samples, the sequence information derived thereof is a valuable source of information to analyze the use of genetic information during different biological stages. The analysis of sequence information is initiated by multiple alignments of the DNA sequences against one another to reduce the redundancy in the sequence set derived from one experiment and for the grouping of sequences with the same orientation marker. Sequences with the identical orientation markers are derived from the same input sample or mixture of samples. The distinction between at least two orientation markers allows tracking back the origin of each sequence and related clones in the cause of the invention. Due to the experimental approach of the invention each sequence should contain information on the flanking region as well as the sequence variation. Thus the invention allows for the identification of boarders of the sequence variants and the identification of the neighboring regions in the initial nucleic acid samples. Individual sequence information can be further analyzed by searches in reference databases known to a person skilled in this field of the art. Any methodology, for example bioinformatic method, for alignment and obtainment of information can be used. Information obtained from alternative spliced nucleic acids can be analysed by means of bioinformatic approaches, for example by aligning the alternative sliced information to genomic sequence data by using computational tools (TAP) in order to discover their function. The understanding of the function of alternative spliced molecules is very valuable in research since alternative splicing is implicated in human diseases (Kan et al., 2002, Genome Research, 1837-1845). Searches in reference database could include but are not limited to alignments to partial and full-length cDNA as well as genomic DNA sequences. The initial sequence information may be extended by alignments to reference sequences, which may allow for a more throughout sequence analysis on the use of the genetic information and proteins derived thereof. In yet another

embodiment the invention can be used and applied for the identification and analysis of introns and exons within transcribed regions of the genome and their selective use within spliced mRNA molecules. Here the invention can provide also relevant information on the coding regions of differentially spliced pre-mRNA molecules and the proteins derived thereof. In yet another embodiment the invention provides intron or exon specific nucleic acid molecules for further manipulation or as experimental tools for the cloning and characterization of differentially spliced mRNAs.

The invention provides effective means for the analysis of sequence variations by matching two or more pluralities of nucleic acids. Out of the selective enrichment of DNA hybrids consisting of loop structures plus double-stranded flanking regions and assembled out of two DNA strands with distinct orientations to mark their origin, the invention allows for the isolation and characterization of those sequence variations comprising and indicating the differential use of related genetic information between the samples. Thus the invention provides novel means for the analysis of differentially spliced pre-mRNA molecules in any biological context. Due to the universal layout of the approach, the invention permits for but is not limited to the analysis of highly complex nucleic acid mixtures by comparing entire pools of mRNA or cDNA molecules derived from mRNA preparations or cDNA libraries. The invention can also be applied in a more focused manner where only different splice variants of the same pre-mRNA or a given transcribed region in the genome are investigated. By applying the invention nucleic acid molecules and sequence information derived thereof can be obtained for further analysis to allow for the functional characterization of known nucleic acids or the identification and isolation of thus far unknown nucleic acids. As the invention can be employed in a wide range of applications in gene discovery and genomic research the approach will greatly contribute to academic and commercial research and development in the field.

Accordingly, the invention provides for a method for identification of isoform nucleic acids and/or polypeptides by using the information obtained by the analysis of the isoform sequences recovered according to any embodiment of the invention. The invention also provides for a method for the detection and/or isolation of nucleic acid isoforms comprising the steps of:

- 1) preparing at least one oligonucleotide probe comprising the whole or part of sequence of an unpaired region identified and/or cloned according to any embodiment of the invention; and

- m) hybridizing the oligonucleotide probe to nucleic acids comprising nucleic acid isoforms;
- n) isolating the nucleic acid isoforms.

The oligonucleotide probe prepared as above can be used to isolate full-length nucleic acid isoform. The oligonucleotide probe may comprise at least one exon or intron. The nucleic acid probe can also be prepared using chemical synthesis methods known in the art using the sequencing and bioinformatics information obtained according to the invention.

The present invention also disclose a nucleic acid probe obtained as above described.

The determination of sequence variation of isoforms prepared according to any embodiment of the invention may comprise the full-length or partial sequencing of the isoform.

According to a further embodiment, the sequence information of the sequence isoforms is used for the design of sequencing primers. The invention therefore also provides for such primers designed with a sequence suitable for sequencing.

The sequencing data of the isoforms obtained by any embodiment according to the invention can be analysed are alignment to the genome, to genomic sequencing data and/or to cDNA sequencing data to obtain genetic information. The information so obtained may be information of alternative splicing.

The invention further relates to the use of the information, obtained from the sequencing and/or analysis method according to the invention, for the detection and/or diagnosis of a disease, disease condition, pathology, a physiological condition, for assessing toxicity, for assessing the therapeutic potential of a test compound and/or for assessing the responsiveness of a patient to a test or treatment. Example of use for this kind of detection, identification and/or diagnosis of disease or physiological and/or pathological condition has been described in US 6,251,590 B1 (incorporated by reference).

The invention furthermore relates to the use of isoforms obtained according to any embodiment of the invention and/or to the nucleic acid probe prepared as above for the preparation of non-soluble supports for hybridization in situ. Accordingly, the invention refers to a non soluble support comprising at least a nucleic acid comprising an unpaired region prepared according to any method of the invention, a nucleic acid complementary to the unpaired region and/or the probe prepared as above, fixed, applied and/or printed thereon.

An example of support having nucleic acid or polypeptide molecules is described in US 6,258,542 B1 (incorporated by reference) for storing and/or delivery.

Other non solid support, preferably on solid matrix, comprising comprising at least an nucleic acid comprising an unpaired region prepared according to any method of the invention, a nucleic acid complementary to the unpaired region and/or the probe prepared as above, fixed, applied and/or printed thereon can be used for hybridization in situ. An example of this support is biochip and/or microarray. Accordingly, any microarray comprising any isoform, unpaired region and/or probe according to the invention is within the scope of the invention. Microarray can be prepared and used according to standard technologies, for example as described in Sambrook and Russel, Molecular Cloning 2002, Cold Spring Harbor Laboratory Press.

Microarray prepared in this way can be used for the identification and isolation of further known or unknown nucleic acid isoforms.

The support or microarray prepared according to the invention can be used for the detection and/or diagnosis of a disease, disease condition, pathology, a physiological condition, for assessing toxicity, for assessing the therapeutic potential of a test compound, for assessing the responsiveness of a patient to a test or treatment, for the detection of nucleic acids and/or for the detection of nucleic acid isoforms. Accordingly, the invention relates to the use of genetic information obtained according to any embodiment of the invention for detecting and/or isolating nucleic acids from a support, microarray, nucleic acid library, biological sample, cell, tissue, organ and/or biopsy.

According to a further embodiment, the invention relates to a computer program and/or software applied on a medium for the analysis of genetic information obtained according to the sequencing and analysis of information as above described. The computer program and/or software applied on a medium can be used for the alignment of the nucleic acid isoforms sequences or information obtained according to any embodiment of the invention to genomic and/or cDNA sequence information. The computer program and/or software can also be used for the prediction, determination and/or analysis of functional domains of polypeptides that derive from nucleic acid isoforms sequence or information obtained according to any embodiment of the invention.

The sequence analysis according to the invention will one or more of the

following elements, features, steps and/or considerations:

- QC on sequencing reads and definition of cutoffs for "useful reads";
- grouping of sequences depending on orientation marker to indicate their origin;
- alignment of reads to group them into clusters to reduce the redundancy in the set for further analysis and statistical analysis of clusters;
- alignment of representative clusters to public or preparatory data sets and analysis of the results;
- mapping of representative clusters to genomic information where possible;
- analysis of genomic regions based on the mapping results, information available on the locus including but not limited to predicted or identified intro-exon structures;
- confirmation of already identified, predicted or newly recognized exons or introns;
- design of computational means to confirm splice sites and to rank them according to their reliability; filtering out artifacts;
- computational means for prediction of or translation into proteins encoded by or modified by exons identified due the cause of the invention;
- design of specific probes for the analysis of exons or introns by hybridization;
- design of specific primers for the analysis of exons or introns by PCR;
- listing of recognition sites for restriction enzymes;
- design of specific primers for the analysis of exons and introns by sequencing reactions.

The present invention further relates to analysis of nucleic acids obtained by any embodiment of the invention. The use of these nucleic acids for the design and preparation of support, in particular macro- and micro-array The analysis of nucleic acids obtained by amplification, for example PCR, by any embodiment of the invention. The analysis of nucleic acids obtained by any embodiment of the invention by amplification, for example PCR, followed by analysis with a set of

restriction enzymes. The analysis of nucleic acids obtained by any embodiment of the invention by partial or extended sequencing using specific sequencing primers. The use of nucleic acids obtained according to any embodiment of the invention for the cloning of cDNA, of a genomic DNA and/or for chemical synthesis of a DNA or RNA molecule. The use of nucleic acids obtained according to any embodiment of the invention for the synthesis of a protein partially or entirely encoded by the nucleic acid. The application of comparison of nucleic acids obtained by any embodiment of the invention derived from two or more different biological samples. The application of comparison of nucleic acids obtained by any embodiment of the invention derived from a cDNA or from a fragment of genomic DNA to samples derived from one or more different biological samples

The present invention will be further explained in more detail with reference to the following examples

EXAMPLE 1

Protocol of Alternative Splicing Exon Library Method

Full-length cDNA libraries from cell line cultures of melanocyte and melanoma were constructed using the method developed by Carninci et al. Genome Res. 2000 Oct;10 (10); Carninci et al. Genomics. 2001 Sep;77 (1-2):79-90. We can use other method by developed by Maruyama, K., Sugano, S., 1994. Gene 138, 171-174. Lambda vector pFLCII (Derivative of the ampicillin-resistant plasmid pBlueScriptII-SK(+), Carninci et al., 2001, Genome Research, Vol.77, (1-2), 79-90). cDNA sequences were inserted into vector with the *Xhol* site at the 5' end of the cDNA and the *BamHI* site at the 3' end.

We sequenced the 5' ESTs using the T7 primer and the 3' ESTs using the T3 primer. The following can be used for the library construction. Stock of the library-phage solution was made by adding 70 ml of DMSO (Dimethyl Sulfoxide, Wako Chemical, Japan) to 930 ml of phage solution and mixed gently manually. The stock was kept at -80 degree C.

Part 1. DNA extraction from amplified phage.

1ml of phage stock solution was mixed gently with addition of RNase, 10u/ μ l and DNase, 1u/ μ l (both Promega), 2 μ l of each enzyme, respectively. Solution was

incubated on 37 degree C for 20 min. After that, 500 μ l of pre-swollen microgranular anion exchanger DE52 (Diethylaminoethyl cellulose, Whatman) was applied with keeping manual mixing for about 10min. Mixture was centrifuged for 1min at room temperature using 10,000rpm. Supernatant was transferred to a 1.5ml new tube and was centrifuged with the same condition as above. After the second centrifugation supernatant was transferred to 2ml new tube and was incubated on 37 degree C for 5min with 100 μ l of 1M ZnCl₂. After centrifugation white pellet was visible and supernatant was discarded. Pellet was well re-suspended with 100 μ l 0.5M EDTA and 900 μ l 7M of Gu-HCl and 100 μ l of matrix (Diatomaceous Earth, Sigma) were applied. After gentle and well mixing for about 5min., solution was centrifuged, 800 μ l of upper phase was discarded and the remaining part (about 400 μ l) was applied to the filter unit (Empty Micro Bio-Spin column BIORAD), placed into 1.5ml tube. Solution was spin down by brief centrifugation for 1 min at 12,000 rpm at room temperature and flow through was discarded. Filter was washed with 400 μ l 7M Gu-HCl, wash solution (twice) and 80% ETOH (twice) with 400 μ l for each time. Filter unit was transferred into 1.5ml tube and 100 μ l of pre-warmed TE was applied in the middle of filter. After 2min. it was centrifuged and 5 μ l of DNA solution was applied to the agarose gel (NuSieve GTG Agarose, TAKARA) (according to Sambrook and Russel, 2001, as above) for concentration and quality checking. DNA solution was further purified using S400 column (Amersham Pharmacia). Sample was applied and flowed trough the column using centrifuge on 3000 rpm for 1min. at 4 degree C.

PCR amplification of inserts.

DNA solution has been used further for PCR amplification of inserts. PCR primers were designed for the vector pFLCII (Carninci et al., September 2001, Vol.77, (1-2), 79-90) part with possible close approach to the sequences of inserts. Phage promoter sequences T3 and T7 were attached to the PCR primers and incorporated to both the PCR products. Reaction conditions were as follows: 2.5 μ l of each 10 μ M of primer: T3GW1:

GAGAGAGAGAATTAACCTCACTAAAGGGACAAGTTGTACAAAAAAGC

(SEQ ID NO:1) and T7GW2:

GAGAGAGAGAATTAACCTCACTAAGGGACCACTTGTACAAGAAAGC

(SEQ ID NO:2). Template 4 μ l (about 40ng), 2XGC buffer 50 μ l, 2.5mM dNTPs 16 μ l, H₂O 25 μ l. Hot start at 95 degree C, add 1 μ l LA Taq (all TAKARA, Japan). PCR was

performed using 10-20 cycles: 95 degree C for 1min. 55 degree C for 30sec. and 72 degree C for 8 min. After reaction, proteinase K digestion was conducted followed by extraction with phenol/chloroform and chloroform (Carninci and Hayashizaki, Methods Enzymol. 1999; 303:19-44), and cDNA was precipitated and dissolved in 100 μ l of H₂O.

RNA synthesis.

RNA was synthesized was carried out by using T3 RNA polymerase (Life Technologies, BRL, 50u/ μ l), to prepare sense run-off RNAs. T7 RNA polymerase (Life Technologies, BRL, 50u/ μ l) was used to prepare antisense run-off RNAs, 10 μ l of PCR sample (3 μ g) has been used as a template and reaction mixture was incubated for 5hrs. at 37 degrees C. Reaction was performed using the following condition: 3 μ l of T7 or T3 RNA polymerase was added 40 μ l of 5xT7/T3 buffer(Life Technologies, BRL), 20 μ l of 0.1M DTT (Life Technologies, BRL), 1.6 μ l of 10mg/ml BSA(Life Technologies, BRL), 10 μ l of 10mM rNTP (Boehringer Mannheim), 115.4 μ l of H₂O with total volume of 200 μ l.

Solution gradually turned to the white and RNA was synthesized. After that, DNaseI (RQ1, RNase-free, Promega, 1u/ μ l) treatment was performed for about 30min. With addition of 20 μ l of 10mM CaCl₂ and 1 μ l of DNase. Sample was dissolved with 100 μ l of water and further purification with QIAGEN purification Kit(QIAGEN) was employed in accordance with the manufacturer's instructions. Final volume of solution was adjusted in 100 μ l of water. Then, proteinase K digestion was conducted followed by extraction with phenol/chloroform and chloroform, and cDNA was precipitated.

1st strand cDNA preparation.

A solution of 5 μ g of RNA sense strand (31 μ l) were combined to 5 μ l of first-strand primer (SEQ ID NO:2) for a total volume of 36 μ l (solution A). 5 μ g of RNA antisense strand (31 μ l) were combined to 5 μ l of the other first-strand primer (SEQ ID NO:1) for a total volume of 36 μ l (solution B). Each of the two solutions (sol A) and (sol B), independently, was denatured at 65 degrees C for 10 min and put in two tubes (one containing denatured sol A and the other containing denatured sol B). Simultaneously, 100 μ l of 2X of buffer GC (TAKARA), 20 μ l of 2.5mM dNTPs, 40 μ l of saturated trehalose (approximately 80%, low metal

content; Fluka Biochemika), and 4 μ l of Superscript II reverse transcriptase (Invitrogen) (200 u/ μ l) were combined to a final volume of 164 μ l (solution C). Further, 0.2 μ l of [32P]dGTP were placed in a third tube. Solution A was mixed on ice with solution C, and an aliquot (20 %) of the mixture was quickly added to the tube containing the [32P]dGTP. First-strand cDNA synthesis was performed in a thermocycler with a heated lid (MJ Research) according to the following program: step 1) 45 degree C for 2 min; step 2) gradient annealing: cooling to 35 degree C over 1 min; step 3) complete annealing: 35 degree C for 2 min; step 4) 50 degree C for 5 min; step 5) increase to 60 degree C at 0.1 degree C per second; step 6) 55 degree C for 2 min; step 7) 60 degree C for 2 min; step 8) return to step 6 and repeat for 10 additional cycles. Incorporation of radioactivity permitted estimation of the yield of cDNA (Carninci and Hayashizaki, Methods Enzymol. 1999;303:19-44). The cDNA obtained was treated with proteinase K, extracted with phenol/chloroform and chloroform, and ethanol-precipitated using 5M NaCl.

The same procedure carried out for solution A was performed for solution B and cDNA obtained and treated in the same way.

RNA removal.

Pellet was dissolved with 100 μ l of H₂O and treated with the same volume of 150 mM NaOH / 15mM EDTA. After incubation at 45 degree C for 10 min, following solutions were added: 100 μ l of 1M Tris-HCl pH7.0 (we can combine two samples on this step), 2 μ l RnaseI (10U), 2 μ l RNaseH (120u) (TAKARA) and incubated 37 degree C, 15min. Again sample was treated with proteinase K, extracted with phenol/chloroform and chloroform, and ethanol-precipitated using 5M NaCl. Pellet dissolved in 100 μ l of water was applied to S400 column. During this step it is possible to use the same column for the samples with the same direction. Sample was precipitated with Isopropanol and washed twice with 80% of ethanol.

Part 2. Hybridization and ExoVII - Restriction Enzyme treatment.

Hybridization was carried out at Cot values of 1 to 20 in a buffer containing 40 percent formamide (from a deionized stock), 0.375M NaCl, 25 mM HEPES (pH 7.5), and 2.5 mM EDTA. Hybridization was carried out at 42 degree C. in a dry oven for 14hrs. After hybridization, the sample was precipitated by adding 2.5 volumes of

absolute ethanol and incubated for 30 minutes on ice. The sample was then centrifuged for 10 min at 15,000 rpm and washed twice with 70% ethanol; the hybrids were resuspended in 90 μ l of water on ice.

Exonuclease VII treatment: for degradation of un-hybridized single stranded DNA was performed by addition of 10XL buffer (TAKARA) and 0.5 μ l of enzyme. Reaction mix was incubation at 37 degree C for 40min. Later remained hybrids were treated with proteinase K, extracted with phenol/chloroform and chloroform, and ethanol-precipitated using 5M NaCl. Sample was resolved in 85 μ l of TE. 5 μ l of sample has been used for S1 nuclease check. We added of 0.5 μ l 10XS1 buffer (300mM Na acetate pH 4.5, 150mM NaCl, 0.05mM ZnSO₄) (TAKARA) to the sample, took 2 μ l from the buffer-sample mixture and put on DE81 paper (Whatman) and checked the radioactivity (standard method). After that we add 2 μ l of enzyme S1 (30u) and incubate at 37C for 30min, took 2 μ l and put them on DE81 paper (Whatman), S1 sensitive rate was calculated (Carninci and Hayashizaki, Methods Enzymol. 1999;303:19-44). Restriction Enzyme Digestion was done with the addition to the reaction mix (sample 80 μ l, 10X1 buffer 10 μ l, BSA μ l) of 2 μ l *Hpa*II and 1.5 μ l *Hpy*CH4IV. After incubation at 37 degree C or 2h, 2 μ l 5M NaCl and 1.5 μ l *Ac*I was applied and incubation was continued for another 2hrs. All three restriction enzymes generate the same CG 5' overhangs that will be farther used for the linker ligation. The three restriction enzymes used here in the EXAMPLES were selected to provide the same cloning site at the end of the fragments to allow for their direct ligation to the same linker as exemplified in EXAMPLES. However, the invention is not limited to the use of these enzymes as any other 4bp cutter or as any other combination of 4bp cutters or as any other combination of one or more 4bp cutters together with any other restriction enzyme can be applied. In case of the use of other restriction enzymes than those used in this EXAMPLES the cloning sites of the linkers have to be adapted or the eventually sticky ends derived from the cleavage of the DNA have to be converted into blunt ends. Such adaptations of the linkers or the conversion of single stranded overhangs can be performed by standard techniques known to a person trained to the state of the art of molecular biology. Digested cDNA hybrids were treated with proteinase K, extracted with phenol/chloroform and chloroform, and ethanol-precipitated using 5M NaCl.

Part 3. Capture-Release.

The next step has been done to capture un-hybridized alternatively spliced exon

loops (also called unpaired regions) using biotinylated random N'25mer oligonucleotides (Invitrogen). First of MPG-streptoavidin magnetic beads (CPG Inc.) were pretreated: 500ul of Magnetic beads, 5ul of 20ug/ul tRNA were incubated on ice with occasional mixing for about 3min. Washed with 1XCTAB Buffer (0.2M

NaCl, 1mM CTAB (Hexadecyltrimethylammonium bromide, Sigma), 10mM EDTA, 25mM Tris-HCl pH7.5) 3 times and added 500ul of 1XCTAB Buffer, 5ul of 20 μ g/ul tRNA. Capture-Release was performed with N'25mer random oligonucleotides (Sambrook et al. Molecular cloning Lab. Manual, CSHL press, 1989) 5 μ l (5 μ g) first incubated on 94 degree C for 30sec It was put on ice and 5 μ g cDNA (hybridized) were applied to the mixture on ice. Then, it was incubated at 37 degree C for 3min. room temperature and the same volume of 2XCTAB Buffer (0.4M NaCl 2mM CTAB 20mM EDTA) was added at room temperature and incubated at 45 degree C for 20min (incubation can also be carried out at 37 degrees C for 20min or at room temperature for 20min). After incubation, the sample was mixed with tRNA(Sigma) treated magnetic beads, rotated at room temperature for 30min and washed with 500ul 3M TMA Buffer (Tetramethylammonium Chloride, Sigma)(3M TMA, 20mM EDTA, 50mM Tris-HCL pH 7.5) 4 or 5 times. The radioactivity of the labeled samples was measured before and after the procedure in order to estimates the yield. 50ul of 0.25X solution containing 4M Guanidium Thiocyanate, 0.5% n-lauryl sarcosine, 25mM Sodium Citrate pH7.0100mM beta-mercaptoethanol with 0.5% Biotin and incubated 37 degree C for 10min. Supernatant was recovered and radioactivity was measured again. Steps were repeated until 80% or more cDNA hybrid was recovered. Sample was precipitated with isopropanol and in order to remove free biotin purification for 2-3 times has been done using Sepadex G50 (Amersham Pharmacia). Herc capture release step can be repeated at least once again.

Part 4. linker ligation, PCR and Cloning.

Y shaped linkers were designed with GC 3' overhangs that could ligate to 5' C/G overhangs generated after the treatment of DNA hybrids with *Hpa*II, *Hpy*CH4IV and *Ac*I. 40ng/ μ l of ASEL9. The two strands of the Y-shaped linker were the following:
Up-5' AAAAAGCAGGCTCGAGTCGAGTCGACGAGAGAGGC (SEQ ID NO:3);
Down 3' P-CGGCCTCTCTGGATCCGAATTACCCAGCTT (SEQ ID NO:4). 2.5l μ l linkers were ligated to the 5 μ l(about 200ng) of DNA and for the

complete reaction following reagents were added: 10XT4 ligase Buffer 0.75μl, T4 DNA Ligase (both NEB), 1μl of H₂O and incubated at 16 degree C overnight. Proteinase K treatment, extraction with phenol/chloroform and chloroform, and ethanol-precipitation using 5M NaCl was performed after the ligation step. Sample was resolved in 8ul of TE and applied on electrophoresis (2% NuSieve GTG agarose, TAKARA). Portions of 60-80bp of the above gel (for linker removal) were cut out and purified by Gel extraction kit(QIAGEN), 60μl of water was applied to the filter unit for the recovering of cDNA hybrids. PCR was performed to amplify each strand of the hybrid containing alternatively spliced exons. Reaction was performed using following conditions: 0.75μl of 10mM primer ASEL9-1

GTGTGTGCGGCCGCACAAGTTGTACAAAAAAGCAGGCTCGAGTCGA

(SEQ ID NO:5)

75μl of 10mM ASEL9-2

CTTCTTGCAGGCCGCACCACTTGTACAAGAAAGCTGGGTGAATTGGATC

(SEQ ID NO:6)

2ml of 10X Extaq Buffer (TAKARA, Japan), 4ul 2.5mM dNTPs (TAKARA, Japan), 0.4μl *dGTP, 5μl of template in total volume of 20μl. Reaction mix was placed on PCR cycler(GeneAMP 9700, Applied Biosystems) with following conditions: 95 degree C of hotstart add ExTaq 0.3μl (TAKARA, Japan), 95 degree C 30sec, 55 degree C for 1min, 72 degree C for 2min about 4 or 8cycles for the preparation of double stranded DNA for cloning purpose only. In another embodiment of the invention the PCR reaction can be performed with 20 cycles, or in yet another embodiment with 30 to 40 cycles to obtain sufficient amount of the PCR product for the direct use of the PCR product in other application rather than the cloning only. Proteinase K digestion was conducted followed by extraction with phenol/chloroform and chloroform (Carninci and Hayashizaki, Methods Enzymol. 1999; 303:19-44), and sample was dissolved with 40μl of TE.

Cloning.

Cloning part included vector preparation (digestion and fragment purification with QIAGEN kit, QIAGEN), restriction digestion of cDNA fragmentes with *Bam*HI and *Sall* and cloning of fragmentes into the vector. Vector pFLC1 (Carninci et al., September 2001, Vol.77, (1-2):79-90). was double digested with 1μl of *Sall* and 1μl *Bam*HI using 10μl 10X*Sall* buffer (all NEB) and 10μl of 10X BSA in total 100μl and incubated at 37 degree C for 1hr. After Proteinase K treatment, extraction with

phenol/chloroform and chloroform, and ethanol-precipitation using 5M NaCl, linear fragment of the vector was resolved in 100 μ l of and applied on electrophoresis (0.8% NuSieve). The DNA fragment were cut out from the gel and purified by Gel Extraction kit (QIAGEN). Vector was dissolved in 100 μ l of water. Digestion of PCR product as also performed with 1 μ l of Sall and 1 μ l BamHI using 10 μ l 10XSall buffer (all NEB) and 10 μ l of 10X BSA in total 100 μ l and incubated at 37 degree C for 1hr. After Proteinase K treatment, extraction with phenol/chloroform and chloroform, and ethanol-precipitation using 5M NaCl, linear fragment of the vector was resolved in 100 μ l of and applied on electrophoresis (0.8% NuSieve). The probable location of dimmer was cut out from the gel and purified by Gel extraction kit (QIAGEN). Vector was dissolved in 100 μ l of water.

Then, sample and vector were mixed and precipitated with 99% ETOH. Pellet was washed once with 70% ETOH and dried. After that the pellet was resolved directly with T4 ligation mixture (TAKARA), which was incubated at 16 degree C for 12hrs and then 5min. at 65 degree C. Later, ligation mixture was transformed by electrophoration into DH10B *E. coli* competent cells.

Clone Isolation and Sequence Analysis.

After the titer check, bacterial clones were collected with commercially available picking machines (Q-bot and Q-pix; Genetics, UK) and transferred to 384-microwell plates. Duplicate plates were used to prepare plasmid DNA. *E. coli* clones containing vector DNAs from each of the 384-well plates were divided and grown in four 96-deepwell plates. After overnight growth, plasmids were extracted either manually (Itoh et al. 1997, Nucleic Acids Res 25:1315-1316) or automatically (Itoh et al. 1999, Genome Res. 9:463-470). Quality of insert was checked by digestion of individual clones with *Pvu*II and applying on 0.8% agarose gel electrophoresis. Sequences were typically run on a RISA sequencing unit (Shimadzu, JAPAN) or using the Perkin Elmer-Applied Biosystems ABI 377 in accordance with standard sequencing methodologies such as described by Shibata et. al. Genome Res. 2000 Nov; 10(11).

Sequencing results. The above experiment made possible to obtain totally 46.159 clones. Inserts from all clones were sequenced using sequence line method described by Shibata et. al. Nov;10(11). Genome research 2000. It resulted in insert identification and mapping to the mouse genome from as many as 37.150 clones.

The rest of data were difficult to localize mostly because of the small size (>=95% >=100bp). Later on, all 37.150 clones were organized in 6.052groupes (each group included at least 2 clones), upon their sequence origin and this was followed with identification of alternative exon variants divided in total 467 subgroups .

EXAMPLE 2

PCR amplification of inserts.

The present example has been carried out in the same way as EXAMPLE 1, with the difference that PCR has been carried out using the following T3GW2 and T7GW1 PCR primers in the first part of lambda-FLCII instead of primers T3GW1 and T7GW2, respectively.

Primer T3GW2:

GAGAGAGAGAATTAACCTCACTAAGGGACCACTTGTACAAGAAAGC

(SEQ ID NO:7)

and T7GW1:

GAGAGAGAGTAATACGACTCACTATGGGACAAGTTGTACAAAAAAGC

(SEQ ID NO:8).

EXAMPLE 3

This example as been carried out like EXAMPLE 1 with the difference that Part 4. Cloning has been carried out as follows.

Ligation to *Cla*I (Takara, Japan) digested pBlueScriptII (Stratagene, US) with T4 ligase 16 degree C overnight, EtOH precipitation, resolve 5μl 1ul use for electrophoration to DH10B, titer check insert quality check with *Pvu*II, and sequencing. All the steps as above were carried out in the same way as Example 1.

EXAMPLE 4

A Full-length cDNA libraries that are used for the a comparative analysis of alternative splicing, such as melanocyte and melanoma, are arrayed on 384 well plate (Shibata et al, Genome Res. 2000 Nov;10(11):1757-71.) and clones are transferred to nylon membranes (Gress TM et al, Mamm Genome. 1992;3(11):609-19.). Information derived from the alternative splicing such oligonucleotides are used as hybridization probe as in Gress

et al. Colonies that are positive for the signals are recovered and subjected to full-insert sequencing (Okazaki et al, *Nature*. 2002 Dec 5;420(6915):563-573.) to obtain full-length information and physical clones of alternatively spliced cDNA.

EXAMPLE 5

Full-length cDNA libraries that have been used for the a comparative analysis of alternative splicing, such as melanocyte and melanoma, were arrayed on 384 well plate (Shibata et al, *Genome Res.* 2000 Nov;10(11):1757-71.) and followed by sequencing of 5' and/or 3' ends. After grouping the cDNAs (Konno et al, *Genome Res.* 2001 Feb;11(2):281-9.) they were aligned to fully sequenced cDNA clones or genome (Okazaki et al, *Nature*. 2002 Dec; 420(6915):563-573). Genome sequence and of a full-length were aligned into transcriptional units as described (Okazaki et al, *Nature*. 2002 Dec 5;420(6915):563-573.) together with the 5' and/or 3' end sequences of the full-length cDNA libraries for which detection of alternative splicing was desired. Then, the information obtained at examples 1-3, which consists of part of cDNAs, was used for alignment to the transcriptional units previously obtained. This mapping allowed us listing up the candidate full-length cDNA that correspond to alternative splicing fragments of cDNAs of examples 1-3.

After *in silico* identification of the candidate clones, the candidate cDNAs were picked-up and subjected to full-insert sequencing as described (Okazaki et al, *Nature*. 2002 Dec 5;420(6915):563-573) and alternatively spliced full-length cDNAs were obtained for further functional studies.

EXAMPLE 6

Full-length cDNA libraries that have been used for the a comparative analysis of alternative splicing, such as melanocyte and melanoma, were converted into plasmid DNAs (Carninci et al, *Genomics*. 2001 Sep;77(1-2):79-90.) and then into single strand DNAs (Bonaldo et al., *Genome Res.* 1996 Sep;6(9):791-806). The genetic information was used to prepare biotinylated oligonucleotides (Invitrogen) corresponding to the alternatively spliced cDNA (as in examples 1-3). Subsequently, single

strand cDNA and biotinylated were mixed and hybridized as described in the Gentrap kit (Invitrogen) following the instruction of manufacturer. Alternatively splicing full-length cDNA from the libraries of interest were then recovered and after palting on agarose (Sambrook et al), the colonies were picked, subjected to one pass sequencing (Shibata et al, Genome Res. 2000 Nov;10(11):1757-71) and then the clones were subjected to full insert sequencing (Okazaki et al, Nature. 2002 Dec 5;420(6915):563-573), obtaining alternatively spliced full-length cDNA.

SEQUENCE LISTING

<110> Riken

K.K.Dnaform

<120> METHOD FOR IDENTIFYING, ANALYSING AND/OR CLONING
NUCLEIC ACID ISOFORMS

<130> P021480

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 49

<212> DNA

<213> Artificial

<220>

<223> PCR Primer: T3GW1

<400> 1

gagagagaga aataaccctc actaaaggga caagtttgta caaaaaagc

49

<210> 2
<211> 47
<212> DNA
<213> Artificial

<220>
<223> PCR primer: T7GW2

<400> 2
gagagagaga attaacctca ctaagggacc acttigtaca agaaagc

47

<210> 3
<211> 35
<212> DNA
<213> Artificial

<220>
<223> Up strand of the Y-shaped linker

<400> 3
aaaaagcagg ctcgagtcga gtcgacgaga gaggc

35

<210> 4
<211> 32
<212> DNA
<213> Artificial

<220>
<223> Down strand of the Y-shaped linker

<400> 4
cggcctctc cgatccgaa ttcacccagc tt

32

<210> 5

<211> 47

<212> DNA

<213> Artificial

<220>

<223> PCR primer ASEL9-1

<400> 5

gtgtgtgcgg ccgcacaagt ttgtacaaaa aagcaggctc gagtcga

47

<210> 6

<211> 50

<212> DNA

<213> Artificial

<220>

<223> PCR primer ASEL9-2

<400> 6

tttcgtgcgg ccgcaccact ttgtacaaga aagctgggtg aattcggatc

50

<210> 7

<211> 47

<212> DNA

<213> Artificial

<220>

<223> PCR Primer T3GW2

<400> 7

gagagagaga attaacatca ctaagggacc actttgtaca agaaagc

47

<210> 8

<211> 48

<212> DNA

<213> Artificial

<220>

<223> PCR primer T7GW1

<400> 8


gagagagagt aatacgactc actatggac aagttgtac aaaaaagc

48

【書類名】


外国語図面

【図 1】

Figure 1 - Principle of mRNA Processing

【図2】

Figure 2 – Steps Involved in the Invention



【図3】





Figure 3 – Preparation of Strand Specific Hybridization Probes

【図4】

Figure 4 – Preparation of PCR Products



【図5】





Figure 5 – Sample-specific ssDNA Synthesis

【図 6】



Figure 6 – Hybridization of Sample-specific ssDNA Molecules

Hybrids containing loop structures

Complete or partial match




No match




【図7】

Figure 7 – Incubation of Hybridization Products with ExonucleaseVII

Hybrids containing loop structures




Complete or partial match



【図8】

Figure 8 – Incubation of Hybridization Products with 4bp Cutters

Hybrids containing loop structures
Complete or partial match



【図9】




Figure 9 – Capture of Loop Structures with Biotinylated and Randomized Oligonucleotide

【図10】






Figure 10 – Structure of Y-shape like asymmetric Linkers

【図11】

Figure 11 – Linker Ligation Applying Y-shape like asymmetric Linkers



【図12】



【書類名】 外國語要約書

1. Abstract

The present invention provides a method for identifying, analysing and/or cloning nucleic acid isoforms comprising the steps of: preparing at least two nucleic acid isoforms, complementary to each other; hybridizing the at least two complementary nucleic acid isoforms and forming double strand RNA/RNA or DNA/DNA hybrids comprising unpaired regions; recovering the RNA/RNA or DNA/DNA hybrids comprising unpaired regions from not hybridized nucleic acids and from nucleic acids not comprising unpaired regions ; and identifying, analysing and/or cloning the recovered nucleic acid fragment comprising unpaired regions.

認定・付加情報

特許出願の番号 特願2002-360972
受付番号 50201884285
書類名 特許願
担当官 田丸 三喜男 9079
作成日 平成15年 2月17日

<認定情報・付加情報>

【提出日】 平成14年12月12日

次頁無


出証特2003-3112386

【書類名】 出願人名義変更届（一般承継）
【提出日】 平成15年12月 1日
【あて先】 特許庁長官殿
【事件の表示】
【出願番号】 特願2002-360972
【承継人】
【識別番号】 503359821
【住所又は居所】 埼玉県和光市広沢2番1号
【氏名又は名称】 独立行政法人理化学研究所
【承継人代理人】
【識別番号】 100075812
【弁理士】
【氏名又は名称】 吉武 賢次
【提出物件の目録】
【物件名】 権利の承継を証明する書面 1
【援用の表示】 平成15年11月20日提出の特許第1575167号外98件
にかかる一般承継による特許権の移転登録申請書
【物件名】 登記簿謄本 1
【援用の表示】 平成15年11月20日提出の特許第1575167号外98件
にかかる一般承継による特許権の移転登録申請書
【物件名】 委任状 1

【物件名】

委任状

【添付書類】

(1)  735

委 任 状

私は、

識別番号 100075812 弁理士 吉 武 賢 次 氏

を代理人と定めて下記事項を委任する。

95454

1. 別紙目録に記載の特許出願に関する出願人名義変更届をする件
2. 上記各項の手続を処理するため復代理人を選任及び解任する件

以 上

平成 15 年 11 月 13 日

住所又は居所


埼玉県和光市広沢 2 番 1 号

氏名又は名称

独立行政法人 理化学研究所

代 表 者

理事長 野 依 良 治



目録(1)

1. 特願昭63-235737	51. 特願平07-327372
2. 特願平05-044143	52. 特願平08-000652
3. 特願平05-127257	53. 特願平08-026368
4. 特願平05-127258	54. 特願平08-030850
5. 特願平05-213675	55. 特願平08-041279
6. 特願平05-306164	56. 特願平08-045903
7. 特願平05-328611	57. 特願平08-051604
8. 特願平05-336746	58. 特願平08-065715
9. 特願平06-035100	59. 特願平08-070071
10. 特願平06-061792	60. 特願平08-105667
11. 特願平06-061793	61. 特願平08-107784
12. 特願平06-069150	62. 特願平08-116473
13. 特願平06-097098	63. 特願平08-123475
14. 特願平06-111624	64. 特願平08-127005
15. 特願平06-121100	65. 特願平08-131746
16. 特願平06-145908	66. 特願平08-132846
17. 特願平06-158670	67. 特願平08-132854
18. 特願平06-158671	68. 特願平08-142676
19. 特願平06-165751	69. 特願平08-158078
20. 特願平06-165752	70. 特願平08-167401
21. 特願平06-181857	71. 特願平08-196331
22. 特願平06-235742	72. 特願平08-197050
23. 特願平06-238603	73. 特願平08-197051
24. 特願平06-244764	74. 特願平08-211948
25. 特願平06-248486	75. 特願平08-216506
26. 特願平06-252942	76. 特願平08-216508
27. 特願平06-268723	77. 特願平08-222352
28. 特願平06-293933	78. 特願平08-231066
29. 特願平06-301372	79. 特願平08-233442
30. 特願平06-323795	80. 特願平08-236685
31. 特願平06-324490	81. 特願平08-251410
32. 特願平06-507966 (子願2002-12430)	82. 特願平08-262051
33. 特願平07-007185	83. 特願平08-302896
34. 特願平07-069255	84. 特願平08-308335
35. 特願平07-082880	85. 特願平08-308336
36. 特願平07-083142	86. 特願平08-311467
37. 特願平07-117933	87. 特願平08-315093
38. 特願平07-133487	88. 特願平08-317622
39. 特願平07-205141	89. 特願平08-320241
40. 特願平07-214659	90. 特願平08-506395
41. 特願平07-217276	91. 特願平09-002295
42. 特願平07-236185	92. 特願平09-010602
43. 特願平07-240684	93. 特願平09-019968
44. 特願平07-249244	94. 特願平09-019969
45. 特願平07-259922	95. 特願平09-019971
46. 特願平07-282716	96. 特願平09-024890
47. 特願平07-302793	97. 特願平09-028982
48. 特願平07-306004	98. 特願平09-046824
49. 特願平07-311711	99. 特願平09-049254
50. 特願平07-311715	100. 特願平09-053478

目録(2)

101. 特願平09-054595	151. 特願平10-045434
102. 特願平09-056654	152. 特願平10-049499
103. 特願平09-057342	153. 特願平10-049867
104. 特願平09-058774	154. 特願平10-051489
105. 特願平09-067611	155. 特願平10-051490
106. 特願平09-074394	156. 特願平10-051491
107. 特願平09-080480	157. 特願平10-051492
108. 特願平09-082965	158. 特願平10-051493
109. 特願平09-091523	159. 特願平10-080740
110. 特願平09-091591	160. 特願平10-060741
111. 特願平09-091694	161. 特願平10-061895
112. 特願平09-096968	162. 特願平10-076139
113. 特願平09-099061	163. 特願平10-085207
114. 特願平09-099109	164. 特願平10-085208
115. 特願平09-104093	165. 特願平10-103083
116. 特願平09-119730	166. 特願平10-103115
117. 特願平09-129068	167. 特願平10-103671
118. 特願平09-134525	168. 特願平10-104093
119. 特願平09-147964	169. 特願平10-113493
120. 特願平09-155364	170. 特願平10-116378
121. 特願平09-159963	171. 特願平10-121456
122. 特願平09-163630	172. 特願平10-127520
123. 特願平09-163631	173. 特願平10-136198
124. 特願平09-171924	174. 特願平10-149603
125. 特願平09-175896	175. 特願平10-150494
126. 特願平09-180423	176. 特願平10-151245
127. 特願平09-189436	177. 特願平10-155838
128. 特願平09-198201	178. 特願平10-155841
129. 特願平09-208866	179. 特願平10-156104
130. 特願平09-221067	180. 特願平10-156108
131. 特願平09-228345	181. 特願平10-198313
132. 特願平09-230870	182. 特願平10-200280
133. 特願平09-253740	183. 特願平10-217132
134. 特願平09-256795	184. 特願平10-217180
135. 特願平09-271782	185. 特願平10-222837
136. 特願平09-291995	186. 特願平10-227939
137. 特願平09-297084	187. 特願平10-229591
138. 特願平09-307627	188. 特願平10-232520
139. 特願平09-308597	189. 特願平10-232590
140. 特願平09-309848	190. 特願平10-238009
141. 特願平09-327140	191. 特願平10-237485
142. 特願平09-327609	192. 特願平10-238144
143. 特願平09-328742	193. 特願平10-245293
144. 特願平09-360327	194. 特願平10-250598
145. 特願平10-002030	195. 特願平10-250611
146. 特願平10-010471	196. 特願平10-252128
147. 特願平10-014152	197. 特願平10-260347
148. 特願平10-015690	198. 特願平10-260416
149. 特願平10-024892	199. 特願平10-268791
150. 特願平10-043335	200. 特願平10-269859

目録(3)

201. 特願平10-272529	251. 特願平11-135137
202. 特願平10-280351	252. 特願平11-135482
203. 特願平10-308533	253. 特願平11-143429
204. 特願平10-309765	254. 特願平11-144005
205. 特願平10-311673	255. 特願平11-147097
206. 特願平10-311674	256. 特願平11-151099
207. 特願平10-311675	257. 特願平11-166247
208. 特願平10-314856	258. 特願平11-173839
209. 特願平10-315751	259. 特願平11-179278
210. 特願平10-338896	260. 特願平11-186052
211. 特願平10-338897	261. 特願平11-193235
212. 特願平10-338898	262. 特願平11-224269
213. 特願平10-338899	263. 特願平11-225060
214. 特願平10-352428	264. 特願平11-225832
215. 特願平10-354665	265. 特願平11-225839
216. 特願平10-363297	266. 特願平11-226176
217. 特願平10-363329	267. 特願平11-234800
218. 特願平10-506788	268. 特願平11-240325
219. 特願平10-532832	269. 特願平11-240910
220. 特願平10-535583	270. 特願平11-241737
221. 特願平11-008183	271. 特願平11-242438
222. 特願平11-013380	272. 特願平11-242490
223. 特願平11-015176	273. 特願平11-253851
224. 特願平11-031724	274. 特願平11-260947
225. 特願平11-035776	275. 特願平11-277759
226. 特願平11-046372	276. 特願平11-278976
227. 特願平11-055835	277. 特願平11-279324
228. 特願平11-055867	278. 特願平11-281632
229. 特願平11-055930	279. 特願平11-303976
230. 特願平11-056957	280. 特願平11-309616
231. 特願平11-057381	281. 特願平11-315036
232. 特願平11-057749	282. 特願平11-321282
233. 特願平11-058103	283. 特願平11-336079
234. 特願平11-061079	284. 特願平11-346467
235. 特願平11-061080	285. 特願平11-354563
236. 特願平11-064193	286. 特願平11-360274
237. 特願平11-064372	287. 特願平11-365899
238. 特願平11-064506	288. 特願平11-373483
239. 特願平11-065136	289. 特願平11-510791
240. 特願平11-074385	290. 特願平11-515324
241. 特願平11-081225	291. 特願2000-001783
242. 特願平11-090383	292. 特願2000-005221
243. 特願平11-091875	293. 特願2000-009363
244. 特願平11-103231	294. 特願2000-010516
245. 特願平11-104509	295. 特願2000-011147
246. 特願平11-106920	296. 特願2000-011623
247. 特願平11-124187	297. 特願2000-016518
248. 特願平11-130771	298. 特願2000-016622
249. 特願平11-130814	299. 特願2000-017112
250. 特願平11-130815	300. 特願2000-018612

目録(4)

301. 特願2000-019195	351. 特願2000-141763
302. 特願2000-019528	352. 特願2000-148843
303. 特願2000-020067	353. 特願2000-152455
304. 特願2000-030321	354. 特願2000-152469
305. 特願2000-034109	355. 特願2000-154484
306. 特願2000-039082	356. 特願2000-161895
307. 特願2000-040355	357. 特願2000-163122
308. 特願2000-041927	358. 特願2000-164584
309. 特願2000-041929	359. 特願2000-179723
310. 特願2000-045318	360. 特願2000-181281
311. 特願2000-045855	361. 特願2000-184259
312. 特願2000-051488	362. 特願2000-184295
313. 特願2000-051650	363. 特願2000-191007
314. 特願2000-052040	364. 特願2000-191265
315. 特願2000-053707	365. 特願2000-192332
316. 特願2000-054949	366. 特願2000-193817
317. 特願2000-056093	367. 特願2000-195384
318. 特願2000-056879	368. 特願2000-196991
319. 特願2000-057564	369. 特願2000-197022
320. 特願2000-057565	370. 特願2000-202801
321. 特願2000-057566	371. 特願2000-216457
322. 特願2000-058133	372. 特願2000-223714
323. 特願2000-058282	373. 特願2000-224970
324. 特願2000-062316	374. 特願2000-225486
325. 特願2000-064142	375. 特願2000-225864
326. 特願2000-064209	376. 特願2000-225978
327. 特願2000-071119	377. 特願2000-226361
328. 特願2000-076122	378. 特願2000-229191
329. 特願2000-085874	379. 特願2000-230551
330. 特願2000-089078	380. 特願2000-237165
331. 特願2000-092693	381. 特願2000-237166
332. 特願2000-100395	382. 特願2000-237533
333. 特願2000-105139	383. 特願2000-246309
334. 特願2000-105917	384. 特願2000-248331
335. 特願2000-107160	385. 特願2000-249232
336. 特願2000-108409	386. 特願2000-256149
337. 特願2000-109638	387. 特願2000-257080
338. 特願2000-109954	388. 特願2000-257083
339. 特願2000-118361	389. 特願2000-260030
340. 特願2000-120874	390. 特願2000-261233
341. 特願2000-123634	391. 特願2000-264743
342. 特願2000-128431	392. 特願2000-265344
343. 特願2000-131049	393. 特願2000-278502
344. 特願2000-131050	394. 特願2000-279557
345. 特願2000-131745	395. 特願2000-292422
346. 特願2000-134427	396. 特願2000-292832
347. 特願2000-136551	397. 特願2000-299812
348. 特願2000-136572	398. 特願2000-307464
349. 特願2000-138977	399. 特願2000-308248
350. 特願2000-141566	400. 特願2000-309581

目録(5)

401. 特願2000-319775	451. 特願2001-071435
402. 特願2000-322056	452. 特願2001-072650
403. 特願2000-333311	453. 特願2001-072668
404. 特願2000-334686	454. 特願2001-072963
405. 特願2000-334969	455. 特願2001-073028
406. 特願2000-343912	456. 特願2001-074964
407. 特願2000-347398	457. 特願2001-074965
408. 特願2000-347865	458. 特願2001-077257
409. 特願2000-358121	459. 特願2001-078671
410. 特願2000-368566	460. 特願2001-084173
411. 特願2000-374626	461. 特願2001-089541
412. 特願2000-375090	462. 特願2001-091911
413. 特願2000-378421	463. 特願2001-092337
414. 特願2000-378942	464. 特願2001-116171
415. 特願2000-378950	465. 特願2001-124294
416. 特願2000-384771	466. 特願2001-124452
417. 特願2000-387016	467. 特願2001-127575
418. 特願2000-394815	468. 特願2001-127576
419. 特願2000-396445	469. 特願2001-135357
420. 特願2000-399940	470. 特願2001-137087
421. 特願2000-400336	471. 特願2001-138103
422. 特願2000-401110	472. 特願2001-142583
423. 特願2000-401245	473. 特願2001-147081
424. 特願2000-401258	474. 特願2001-152364
425. 特願2000-503838	475. 特願2001-152379
426. 特願2000-571733	476. 特願2001-153447
427. 特願2000-571943	477. 特願2001-155572
428. 特願2000-602588	478. 特願2001-163740
429. 特願2000-602900	479. 特願2001-164819
430. 特願2000-618709	480. 特願2001-164997
431. 特願2001-003476	481. 特願2001-165133
432. 特願2001-005615	482. 特願2001-167910
433. 特願2001-007979	483. 特願2001-168784
434. 特願2001-016626	484. 特願2001-171705
435. 特願2001-025030	485. 特願2001-173331
436. 特願2001-037141	486. 特願2001-174421
437. 特願2001-037147	487. 特願2001-174553
438. 特願2001-042501	488. 特願2001-175898
439. 特願2001-044933	489. 特願2001-178169
440. 特願2001-047762	490. 特願2001-179858
441. 特願2001-050645	491. 特願2001-180552
442. 特願2001-053550	492. 特願2001-180554
443. 特願2001-054717	493. 特願2001-187735
444. 特願2001-059115	494. 特願2001-197185
445. 特願2001-059892	495. 特願2001-197897
446. 特願2001-060848	496. 特願2001-200854
447. 特願2001-062703	497. 特願2001-201356
448. 特願2001-065799	498. 特願2001-202971
449. 特願2001-065917	499. 特願2001-203089
450. 特願2001-068285	500. 特願2001-206505

目録(6)

501. 特願2001-206522	551. 特願2001-325367
502. 特願2001-206523	552. 特願2001-326872
503. 特願2001-209305	553. 特願2001-327853
504. 特願2001-212947	554. 特願2001-329023
505. 特願2001-216505	555. 特願2001-332168
506. 特願2001-220219	556. 特願2001-337467
507. 特願2001-226176	557. 特願2001-339396
508. 特願2001-228287	558. 特願2001-339593
509. 特願2001-228374	559. 特願2001-346035
510. 特願2001-235412	560. 特願2001-347316
511. 特願2001-235747	561. 特願2001-347637
512. 特願2001-238951	562. 特願2001-349614
513. 特願2001-241023	563. 特願2001-351730
514. 特願2001-243930	564. 特願2001-352189
515. 特願2001-246642	565. 特願2001-353038
516. 特願2001-249976	566. 特願2001-358446
517. 特願2001-254377	567. 特願2001-358581
518. 特願2001-254378	568. 特願2001-359710
519. 特願2001-255589	569. 特願2001-374928
520. 特願2001-256576	570. 特願2001-376591
521. 特願2001-257188	571. 特願2001-378757
522. 特願2001-261158	572. 特願2001-380473
523. 特願2001-266004	573. 特願2001-382537
524. 特願2001-266069	574. 特願2001-382539
525. 特願2001-266454	575. 特願2001-382599
526. 特願2001-267194	576. 特願2001-385258
527. 特願2001-267379	577. 特願2001-385512
528. 特願2001-267863	578. 特願2001-385513
529. 特願2001-272977	579. 特願2001-385538
530. 特願2001-273964	580. 特願2001-388116
531. 特願2001-276053	581. 特願2001-390122
532. 特願2001-279406	582. 特願2001-392087
533. 特願2001-280319	583. 特願2001-392088
534. 特願2001-285145	584. 特願2001-395196
535. 特願2001-291059	585. 特願2001-396120
536. 特願2001-292223	586. 特願2001-397762
537. 特願2001-292224	587. 特願2001-397998
538. 特願2001-293000	588. 特願2001-401139
539. 特願2001-293054	589. 特願2001-515803
540. 特願2001-293936	590. 特願2001-523852
541. 特願2001-294013	591. 特願2001-557672
542. 特願2001-298140	592. 特願2002-000993
543. 特願2001-298402	593. 特願2002-005746
544. 特願2001-307340	594. 特願2002-010344
545. 特願2001-309501	595. 特願2002-011558
546. 特願2001-309508	596. 特願2002-019752
547. 特願2001-309984	597. 特願2002-020329
548. 特願2001-310554	598. 特願2002-022499
549. 特願2001-313430	599. 特願2002-028046
550. 特願2001-319360	600. 特願2002-028109

目録(7)

601. 特願 2002-040151	651. 特願 2002-162157
602. 特願 2002-042829	652. 特願 2002-162211
603. 特願 2002-044340	653. 特願 2002-162365
604. 特願 2002-044640	654. 特願 2002-167759
605. 特願 2002-046188	655. 特願 2002-170068
606. 特願 2002-047799	656. 特願 2002-170902
607. 特願 2002-053190	657. 特願 2002-176435
608. 特願 2002-053575	658. 特願 2002-176583
609. 特願 2002-055272	659. 特願 2002-183722
610. 特願 2002-057253	660. 特願 2002-185966
611. 特願 2002-057565	661. 特願 2002-187362
612. 特願 2002-057935	662. 特願 2002-187957
613. 特願 2002-057963	663. 特願 2002-188281
614. 特願 2002-066249	664. 特願 2002-189265
615. 特願 2002-070624	665. 特願 2002-194627
616. 特願 2002-070987	666. 特願 2002-197812
617. 特願 2002-071924	667. 特願 2002-201443
618. 特願 2002-074902	668. 特願 2002-201575
619. 特願 2002-078164	669. 特願 2002-202118
620. 特願 2002-081467	670. 特願 2002-205814
621. 特願 2002-081502	671. 特願 2002-205825
622. 特願 2002-083081	672. 特願 2002-217714
623. 特願 2002-084139	673. 特願 2002-221188
624. 特願 2002-085017	674. 特願 2002-225469
625. 特願 2002-087342	675. 特願 2002-225724
626. 特願 2002-094681	676. 特願 2002-226859
627. 特願 2002-095132	677. 特願 2002-227286
628. 特願 2002-095389	678. 特願 2002-229686
629. 特願 2002-100431	679. 特願 2002-230562
630. 特願 2002-106561	680. 特願 2002-235294
631. 特願 2002-119320	681. 特願 2002-235737
632. 特願 2002-120371	682. 特願 2002-236838
633. 特願 2002-123347	683. 特願 2002-237058
634. 特願 2002-128854	684. 特願 2002-237092
635. 特願 2002-133717	685. 特願 2002-248946
636. 特願 2002-133749	686. 特願 2002-253322
637. 特願 2002-134313	687. 特願 2002-253689
638. 特願 2002-141187	688. 特願 2002-253697
639. 特願 2002-141438	689. 特願 2002-254096
640. 特願 2002-142260	690. 特願 2002-257924
641. 特願 2002-149471	691. 特願 2002-260788
642. 特願 2002-149931	692. 特願 2002-261499
643. 特願 2002-150541	693. 特願 2002-264969
644. 特願 2002-154688	694. 特願 2002-267114
645. 特願 2002-154695	695. 特願 2002-268987
646. 特願 2002-154823	696. 特願 2002-270917
647. 特願 2002-158237	697. 特願 2002-271375
648. 特願 2002-158352	698. 特願 2002-271473
649. 特願 2002-160277	699. 特願 2002-273996
650. 特願 2002-162148	700. 特願 2002-274469

目録(8)

701. 特願2002-276051	751. 特願2003-012738
702. 特願2002-282746	752. 特願2003-012774
703. 特願2002-286487	753. 特願2003-015968
704. 特願2002-289209	754. 特願2003-016044
705. 特願2002-295332	755. 特願2003-016940
706. 特願2002-296911	756. 特願2003-017397
707. 特願2002-299429	757. 特願2003-021498
708. 特願2002-301875	758. 特願2003-024347
709. 特願2002-303838	759. 特願2003-024620
710. 特願2002-312131	760. 特願2003-025277
711. 特願2002-320102	761. 特願2003-027647
712. 特願2002-320704	762. 特願2003-027648
713. 特願2002-325909	763. 特願2003-031882
714. 特願2002-325920	764. 特願2003-032932
715. 特願2002-332232	765. 特願2003-038206
716. 特願2002-339344	766. 特願2003-040642
717. 特願2002-339392	767. 特願2003-043961
718. 特願2002-339541	768. 特願2003-050153
719. 特願2002-339551	769. 特願2003-050446
720. 特願2002-341195	770. 特願2003-052520
721. 特願2002-343807	771. 特願2003-052602
722. 特願2002-344279	772. 特願2003-052613
723. 特願2002-345597	773. 特願2003-052877
724. 特願2002-347401	774. 特願2003-053023
725. 特願2002-348760	775. 特願2003-054182
726. 特願2002-349042	776. 特願2003-054798
727. 特願2002-354594	777. 特願2003-054799
728. 特願2002-357768	778. 特願2003-054846
729. 特願2002-357900	779. 特願2003-054847
730. 特願2002-358019	780. 特願2003-054848
731. 特願2002-358967	781. 特願2003-054849
732. 特願2002-360972	782. 特願2003-055452
733. 特願2002-360975	783. 特願2003-056628
734. 特願2002-368112	784. 特願2003-061426
735. 特願2002-376555	785. 特願2003-063532
736. 特願2002-376774	786. 特願2003-065013
737. 特願2002-376831	787. 特願2003-071028
738. 特願2002-379214	788. 特願2003-072979
739. 特願2002-380624	789. 特願2003-074168
740. 特願2002-381888	790. 特願2003-076107
741. 特願2002-382170	791. 特願2003-078999
742. 特願2002-383870	792. 特願2003-079598
743. 特願2002-521644	793. 特願2003-079613
744. 特願2002-532458	794. 特願2003-082466
745. 特願2002-546564	795. 特願2003-083318
746. 特願2002-548185	796. 特願2003-083433
747. 特願2002-570743	797. 特願2003-083480
748. 特願2003-003450	798. 特願2003-085193
749. 特願2003-012550	799. 特願2003-089026
750. 特願2003-012694	800. 特願2003-090331

目録(9)

801. 特願2003-091446	851. 特願2003-127135
802. 特願2003-092654	852. 特願2003-127150
803. 特願2003-093642	853. 特願2003-128818
804. 特願2003-094272	854. 特願2003-128897
805. 特願2003-094719	855. 特願2003-129347
806. 特願2003-095770	856. 特願2003-131313
807. 特願2003-095884	857. 特願2003-132280
808. 特願2003-095885	858. 特願2003-132605
809. 特願2003-095886	859. 特願2003-132606
810. 特願2003-095904	860. 特願2003-135591
811. 特願2003-097283	861. 特願2003-136445
812. 特願2003-097327	862. 特願2003-139397
813. 特願2003-101917	863. 特願2003-140684
814. 特願2003-104928	864. 特願2003-142303
815. 特願2003-105362	865. 特願2003-143932
816. 特願2003-107267	866. 特願2003-145221
817. 特願2003-107268	867. 特願2003-145390
818. 特願2003-107647	868. 特願2003-147820
819. 特願2003-107885	869. 特願2003-150690
820. 特願2003-109575	870. 特願2003-153014
821. 特願2003-115750	871. 特願2003-153015
822. 特願2003-115793	872. 特願2003-153016
823. 特願2003-115847	873. 特願2003-153985
824. 特願2003-115888	874. 特願2003-154009
825. 特願2003-116232	875. 特願2003-154841
826. 特願2003-116895	876. 特願2003-155397
827. 特願2003-118161	877. 特願2003-156407
828. 特願2003-118186	878. 特願2003-158017
829. 特願2003-119749	879. 特願2003-161005
830. 特願2003-119930	880. 特願2003-164126
831. 特願2003-120934	881. 特願2003-170051
832. 特願2003-121233	882. 特願2003-170324
833. 特願2003-121261	883. 特願2003-170325
834. 特願2003-121273	884. 特願2003-170326
835. 特願2003-121780	885. 特願2003-170327
836. 特願2003-122245	886. 特願2003-170328
837. 特願2003-123984	887. 特願2003-170329
838. 特願2003-124654	888. 特願2003-170330
839. 特願2003-124655	889. 特願2003-170573
840. 特願2003-124826	890. 特願2003-171576
841. 特願2003-124829	891. 特願2003-171619
842. 特願2003-124833	892. 特願2003-172898
843. 特願2003-124835	893. 特願2003-175819
844. 特願2003-125388	894. 特願2003-177298
845. 特願2003-125403	895. 特願2003-180198
846. 特願2003-125405	896. 特願2003-182958
847. 特願2003-127090	897. 特願2003-192763
848. 特願2003-127093	898. 特願2003-192775
849. 特願2003-127109	899. 特願2003-194837
850. 特願2003-127130	900. 特願2003-197229

目録(10)

901. 特願2003-198340	951. 特願2003-338191
902. 特願2003-204075	952. 特願2003-339542
903. 特願2003-205349	953. 特願2003-340181
904. 特願2003-205710	954. 特願2003-342519
905. 特願2003-206546	
906. 特願2003-207698	
907. 特願2003-207771	
908. 特願2003-207772	
909. 特願2003-207850	
910. 特願2003-270049	
911. 特願2003-271473	
912. 特願2003-272421	
913. 特願2003-275055	
914. 特願2003-277958	
915. 特願2003-279130	
916. 特願2003-283972	
917. 特願2003-284055	
918. 特願2003-286640	
919. 特願2003-289138	
920. 特願2003-293912	
921. 特願2003-296474	
922. 特願2003-298558	
923. 特願2003-299424	
924. 特願2003-303979	
925. 特願2003-304452	
926. 特願2003-304453	
927. 特願2003-305689	
928. 特願2003-305844	
929. 特願2003-306137	
930. 特願2003-307564	
931. 特願2003-313014	
932. 特願2003-315355	
933. 特願2003-318801	
934. 特願2003-321497	
935. 特願2003-322948	
936. 特願2003-324974	
937. 特願2003-326510	
938. 特願2003-327645	
939. 特願2003-327907	
940. 特願2003-328600	
941. 特願2003-328840	
942. 特願2003-330418	
943. 特願2003-330569	
944. 特願2003-331848	
945. 特願2003-332756	
946. 特願2003-333798	
947. 特願2003-333932	
948. 特願2003-334036	
949. 特願2003-334083	
950. 特願2003-336365	

認定・付加情報

特許出願の番号	特願2002-360972
受付番号	20308550725
書類名	出願人名義変更届（一般承継）
担当官	田丸 三喜男 9079
作成日	平成16年 3月17日

<認定情報・付加情報>

【提出された物件の記事】

【提出物件名】	委任状（代理権を証明する書面）	1
---------	-----------------	---

特願 2002-360972

出願人履歴情報

識別番号 [000006792]

1. 変更年月日 1990年 8月28日

[変更理由] 新規登録

住所 埼玉県和光市広沢2番1号

氏名 理化学研究所

特願 2002-360972

出願人履歴情報

識別番号

[501293666]

1. 変更年月日 2002年 3月26日

[変更理由] 住所変更

住所 東京都港区三田1丁目3番35号
氏名 株式会社ダナフォーム

特願 2002-360972

出願人履歴情報

識別番号 [503359821]

1. 変更年月日 2003年10月 1日

[変更理由] 新規登録

住所 埼玉県和光市広沢2番1号
氏名 独立行政法人理化学研究所